Track market-moving stories before they get noisy

Posted by Defense World Staff on Jul 21st, 2026

Andra AP fonden trimmed its holdings in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 14.9% in the first quarter, according to its most recent filing with the SEC. The firm owned 364,485 shares of the company’s stock after selling 63,615 shares during the period. Merck & Co., Inc. makes up about 0.5% of Andra AP fonden’s investment portfolio, making the stock its 26th biggest position. Andra AP fonden’s holdings in Merck & Co., Inc. were worth $43,844,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the business. D.A. Davidson & CO. grew its stake in Merck & Co., Inc. by 4.4% in the 4th quarter. D.A. Davidson & CO. now owns 576,959 shares of the company’s stock valued at $60,731,000 after purchasing an additional 24,576 shares during the period. Farther Finance Advisors LLC increased its position in shares of Merck & Co., Inc. by 48.9% during the 4th quarter. Farther Finance Advisors LLC now owns 97,818 shares of the company’s stock valued at $10,296,000 after purchasing an additional 32,114 shares during the last quarter. Norris Perne & French LLP MI raised its stake in shares of Merck & Co., Inc. by 12.8% during the 4th quarter. Norris Perne & French LLP MI now owns 252,162 shares of the company’s stock worth $26,543,000 after purchasing an additional 28,635 shares during the period. Pinnbrook Capital Management LP raised its stake in shares of Merck & Co., Inc. by 95.2% during the 4th quarter. Pinnbrook Capital Management LP now owns 23,280 shares of the company’s stock worth $2,450,000 after purchasing an additional 11,355 shares during the period. Finally, Cibc World Market Inc. boosted its holdings in shares of Merck & Co., Inc. by 32.6% in the 4th quarter. Cibc World Market Inc. now owns 1,301,744 shares of the company’s stock worth $137,022,000 after buying an additional 320,143 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets MRK has been the subject of several research reports. Guggenheim increased their price target on shares of Merck & Co., Inc. from $140.00 to $145.00 and gave the company a “buy” rating in a research report on Monday, July 13th. JPMorgan Chase & Co. boosted their target price on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Scotiabank increased their target price on shares of Merck & Co., Inc. from $136.00 to $155.00 and gave the company a “sector outperform” rating in a research report on Tuesday, June 30th. Royal Bank Of Canada restated an “outperform” rating and set a $142.00 price target on shares of Merck & Co., Inc. in a research note on Wednesday, July 8th. Finally, CICC Research began coverage on shares of Merck & Co., Inc. in a report on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat, Merck & Co., Inc. has an average rating of “Moderate Buy” and an average price target of $133.94.

View Our Latest Research Report on Merck & Co., Inc.

Merck & Co., Inc. Trading Down 2.4% Shares of Merck & Co., Inc. stock opened at $124.41 on Tuesday. The stock has a market capitalization of $307.27 billion, a P/E ratio of 35.05, a P/E/G ratio of 5.04 and a beta of 0.19. Merck & Co., Inc. has a 52-week low of $76.66 and a 52-week high of $131.74. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The stock’s 50-day simple moving average is $120.37 and its 200 day simple moving average is $117.14.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last issued its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. During the same quarter last year, the business earned $2.22 earnings per share. The company’s quarterly revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, research analysts anticipate that Merck & Co., Inc. will post 2.76 EPS for the current year.

Merck & Co., Inc. Announces Dividend The business also recently announced a quarterly dividend, which was paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th were given a dividend of $0.85 per share. The ex-dividend date was Monday, June 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.7%. Merck & Co., Inc.’s dividend payout ratio is currently 95.77%.

Merck & Co., Inc. Company Profile (Free Report)

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Further Reading Five stocks we like better than Merck & Co., Inc. The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEGlobal-e Online Ltd. $GLBE Shares Sold by Amova Asset Management Americas Inc.

NEXT HEADLINE »Andra AP fonden Purchases 46,000 Shares of Arista Networks, Inc. $ANET

VANCOUVER, BC / ACCESS Newswire / July 21, 2026 / Metallic Minerals Corp. (TSXV:MMG)(OTCQB:MMNGF)(FSE:9MM1) ("Metallic" or the "Company") is pleased to announce that it has completed a non-brokered private placement with Newmont Corporation ("Newmont"), through a wholly owned subsidiary pursuant to its participation rights under the Investor Rights Agreement ("IRA") dated May 18, 2023. Newmont subscribed for 3,224,700 units (each, a "Unit") of the Company at a price of $0.28 per Unit, for gross proceeds of $902,916, reflecting the same terms as the Company's recently closed $10.3 million bought deal financing in June.

Each Unit consists of one common share of the Company (a "Common Share") and one-half of one common share purchase warrant of the Company (each whole warrant, a "Warrant"). Each Warrant entitles the holder to acquire one Common Share at a price of $0.40 per share for a period of 36 months, commencing 61 days following the closing date.

This private placement maintains Newmont's approximately 9.2% ownership interest in the Company. The Company intends to use the net proceeds to advance exploration and development activities at its La Plata copper-silver-PGE-gold and associated critical minerals project in southwestern Colorado, USA, as well as for working capital and general corporate purposes.

The recently updated 2026 NI 43-101 Mineral Resource Estimate at the La Plata project marks a major milestone for the Company. The updated estimate expands the Inferred resource to 181.4 Mt at 0.36% copper equivalent, containing 1,307 Mlbs of copper and 17.0 Moz of silver (1,455 Mlbs CuEq). This updated estimate incorporates platinum, palladium and gold for the first time, with a 45.4 Mt subset now reporting 91,000 oz Pt, 121,000 oz Pd and 60,000 oz Au totaling ~272,000 oz of platinum group elements plus gold, which along with additional priority critical minerals designated by the U.S. government enhances the overall value and metal diversity of the deposit.

Greg Johnson, Chairman and CEO said, "Newmont has been a valued strategic shareholder since 2023, and we have appreciated the collaboration with their technical team via our IRA technical committee. The recently updated and expanded Allard resource remains open to expansion and the district-scale La Plata project has another 20 developing surface targets, which may represent additional porphyry centers. With these financing activities complete field programs are being initiated with additional updates to follow. The fundamentals for copper and critical minerals remain very strong and underscore La Plata's potential to emerge not only as a significant copper and precious metal (Ag, Au, Pt and Pd) resource, but also as a strategic source of critical minerals in the U.S. that are essential to support advanced technologies, energy transition and domestic economic development."

No fees or commissions were paid related to the private placement. The securities issued under the private placement are subject to a statutory hold period expiring four months and one day following the closing date, in accordance with applicable Canadian securities laws and the policies of the TSX Venture Exchange. The private placement is subject to final acceptance of the TSX Venture Exchange.

About Metallic Minerals

Metallic Minerals Corp. is a resource-stage exploration and development company advancing copper, silver, gold, platinum group elements, and other critical minerals at the La Plata project in southwestern Colorado, and high-grade silver, gold, lead and zinc exploration at the Keno Silver project in the Yukon Territory, adjacent to Hecla Mining's Keno Hill silver operations. The Company is also one of the largest holders of alluvial gold claims in the Yukon and is building a production royalty business through partnerships with experienced mining operators.

Metallic is led by a team with a strong track record of discovery and exploration success across multiple precious and base metal deposits in North America and is backed by strategic investment by Newmont Corporation and Eric Sprott. The Company integrates advanced data analytics into its exploration process to support target generation, accelerate discovery, and unlock value across its portfolio.

Metallic's project districts have a history of significant mineral production and benefit from existing infrastructure, including road access and nearby power. The Company's team has been recognized for environmental stewardship practices and is committed to responsible and sustainable resource development, engaging and collaborating with Canadian First Nations, U.S. Tribal and Native Corporations, and local communities to support long-term project advancement.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Website: metallic-minerals.com Phone: 604-629-7800
Email: [email protected] Toll Free: 1-888-570-4420

Qualified Person

The scientific and technical information contained in this news release relating to the La Plata Project mineral resource estimate and the associated NI 43-101 technical report has been reviewed and approved by Scott Petsel, M.S., CPG, P.Geo., President of Metallic Minerals Corp., who is a Qualified Person as defined by National Instrument 43-101 - Standards of Disclosure for Mineral Projects. Mr. Petsel is not independent of the Company.

Forward-Looking Statements

This news release includes certain forward-looking statements within the meaning of applicable securities laws, including statements regarding the intended use of proceeds from the private placement, the receipt of final TSX Venture Exchange approval, the advancement of the Company's projects, the potential for the La Plata project to host or become a source of critical minerals, anticipated demand for critical minerals, the potential for additional porphyry centres and exploration targets, the continued participation and support of Newmont as a strategic shareholder, and other statements that are not historical facts. Forward-looking statements are based on management's current expectations and assumptions and are subject to a variety of risks and uncertainties that could cause actual results to differ materially from those expressed or implied. All statements in this release, other than statements of historical facts including, without limitation, statements regarding potential mineralization, historic production, estimation of mineral resources, the realization of mineral resource estimates, interpretation of prior exploration and potential exploration results, the timing and success of exploration activities generally, the timing and results of future resource estimates, permitting timelines, metal prices and currency exchange rates, availability of capital, government regulation of exploration operations, environmental risks, reclamation, title, statements about expected results of operations, royalties, cash flows, financial position and future dividends as well as financial position, prospects, and future plans and objectives of the Company are forward-looking statements that involve various risks and uncertainties. Although Metallic Minerals believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Forward-looking statements are based on a number of material factors and assumptions. Factors that could cause actual results to differ materially from those in forward-looking statements include failure to obtain necessary approvals, unsuccessful exploration results, unsuccessful operations, changes in project parameters as plans continue to be refined, results of future resource estimates, future metal prices, availability of capital and financing on acceptable terms, general economic, market or business conditions, risks associated with regulatory changes, defects in title, availability of personnel, materials and equipment on a timely basis, accidents or equipment breakdowns, uninsured risks, delays in receiving government approvals, unanticipated environmental impacts on operations and costs to remedy same, the risk that metallurgical recovery of copper, precious metals and critical minerals remains subject to ongoing test work and may not achieve anticipated results, and that markets, demand or U.S. government policy for critical minerals may not develop as anticipated and other exploration or other risks detailed herein and from time to time in the filings made by the Company with securities regulators. There can be no assurance that Newmont will maintain its ownership interest in the Company or exercise any future participation rights, and Newmont may dispose of some or all of its holdings; Newmont's investment in the Company should not be considered an indication of the value of, or a recommendation regarding, the Company's securities. Readers are cautioned that mineral resources that are not mineral reserves do not have demonstrated economic viability. Mineral exploration, development of mines and mining operations is an inherently risky business. Accordingly, the actual events may differ materially from those projected in the forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements except as required by applicable law. For more information on Metallic Minerals and the risks and challenges of their businesses, investors should review their annual filings that are available at sedarplus.ca.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Metallic Minerals Corp.

Posted by Defense World Staff on Jul 21st, 2026

Andra AP fonden boosted its stake in shares of Linde PLC (NASDAQ:LIN – Free Report) by 35.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 60,125 shares of the basic materials company’s stock after buying an additional 15,815 shares during the quarter. Andra AP fonden’s holdings in Linde were worth $29,808,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in LIN. Darwin Wealth Management LLC acquired a new position in Linde during the second quarter worth $25,000. Legacy Wealth Managment LLC ID grew its holdings in Linde by 96.6% in the first quarter. Legacy Wealth Managment LLC ID now owns 57 shares of the basic materials company’s stock valued at $28,000 after purchasing an additional 28 shares during the last quarter. Triumph Capital Management increased its position in shares of Linde by 69.2% in the fourth quarter. Triumph Capital Management now owns 66 shares of the basic materials company’s stock valued at $28,000 after buying an additional 27 shares in the last quarter. Strengthening Families & Communities LLC increased its position in shares of Linde by 134.5% in the fourth quarter. Strengthening Families & Communities LLC now owns 68 shares of the basic materials company’s stock valued at $29,000 after buying an additional 39 shares in the last quarter. Finally, High Note Wealth LLC raised its stake in shares of Linde by 108.6% during the 4th quarter. High Note Wealth LLC now owns 73 shares of the basic materials company’s stock worth $31,000 after buying an additional 38 shares during the last quarter. 82.80% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes A number of equities research analysts recently commented on LIN shares. UBS Group reissued a “buy” rating and issued a $600.00 price objective on shares of Linde in a research note on Tuesday, June 2nd. Sanford C. Bernstein set a $559.00 price target on shares of Linde in a report on Friday. BMO Capital Markets reiterated an “outperform” rating and issued a $560.00 price target on shares of Linde in a research report on Tuesday, May 5th. Seaport Research Partners raised their price objective on shares of Linde from $525.00 to $575.00 and gave the stock a “buy” rating in a research note on Friday, April 17th. Finally, Weiss Ratings upgraded Linde from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $548.67.

Get Our Latest Stock Report on Linde

Linde Trading Down 0.2% Shares of LIN stock opened at $512.05 on Tuesday. The company has a market capitalization of $236.74 billion, a price-to-earnings ratio of 34.00, a PEG ratio of 3.22 and a beta of 0.72. The company has a current ratio of 0.83, a quick ratio of 0.69 and a debt-to-equity ratio of 0.50. The firm has a 50-day moving average price of $516.10 and a 200 day moving average price of $492.13. Linde PLC has a twelve month low of $387.78 and a twelve month high of $548.20.

Linde (NASDAQ:LIN – Get Free Report) last issued its quarterly earnings results on Friday, May 1st. The basic materials company reported $4.33 EPS for the quarter, topping analysts’ consensus estimates of $4.27 by $0.06. The business had revenue of $8.78 billion during the quarter, compared to the consensus estimate of $8.60 billion. Linde had a net margin of 20.44% and a return on equity of 19.80%. The company’s quarterly revenue was up 8.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.95 earnings per share. Linde has set its FY 2026 guidance at 17.600-17.900 EPS and its Q2 2026 guidance at 4.400-4.500 EPS. Research analysts forecast that Linde PLC will post 17.88 earnings per share for the current fiscal year.

Linde Announces Dividend The company also recently announced a quarterly dividend, which was paid on Thursday, June 18th. Shareholders of record on Thursday, June 4th were paid a $1.60 dividend. This represents a $6.40 annualized dividend and a yield of 1.2%. The ex-dividend date of this dividend was Thursday, June 4th. Linde’s payout ratio is presently 42.50%.

Linde Company Profile (Free Report)

Linde (NASDAQ: LIN) is a multinational industrial gases and engineering company that supplies gases, related technologies and services to a wide range of industries. The company traces its current form to the 2018 combination of Germany’s Linde AG and U.S.-based Praxair, creating one of the largest global providers of industrial, specialty and medical gases. Linde’s business model centers on production, processing and distribution of gases as well as the design and construction of the plants and equipment needed to produce them.

Core products and services include atmospheric and process gases such as oxygen, nitrogen and argon; hydrogen and helium; carbon dioxide; and a portfolio of higher‑value specialty and electronic gases.

Read More Five stocks we like better than Linde The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for Linde Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Linde and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAndra AP fonden Purchases 15,800 Shares of Welltower Inc. $WELL

NEXT HEADLINE »Andra AP fonden Purchases 103,374 Shares of Oracle Corporation $ORCL

Posted by Defense World Staff on Jul 21st, 2026

Andra AP fonden reduced its position in shares of Agnico Eagle Mines Limited (NYSE:AEM – Free Report) (TSE:AEM) by 3.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 125,561 shares of the mining company’s stock after selling 4,926 shares during the period. Andra AP fonden’s holdings in Agnico Eagle Mines were worth $25,486,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Capital World Investors boosted its holdings in shares of Agnico Eagle Mines by 2.8% in the 4th quarter. Capital World Investors now owns 21,338,277 shares of the mining company’s stock valued at $3,618,730,000 after buying an additional 572,473 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Agnico Eagle Mines by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 20,979,666 shares of the mining company’s stock worth $3,557,772,000 after purchasing an additional 309,717 shares during the last quarter. Van ECK Associates Corp increased its position in shares of Agnico Eagle Mines by 21.6% during the fourth quarter. Van ECK Associates Corp now owns 17,225,477 shares of the mining company’s stock worth $2,920,258,000 after purchasing an additional 3,062,705 shares in the last quarter. TD Asset Management Inc increased its position in shares of Agnico Eagle Mines by 1.7% during the fourth quarter. TD Asset Management Inc now owns 9,665,456 shares of the mining company’s stock worth $1,641,239,000 after purchasing an additional 165,263 shares in the last quarter. Finally, Mackenzie Financial Corp lifted its holdings in shares of Agnico Eagle Mines by 4.0% in the 4th quarter. Mackenzie Financial Corp now owns 8,687,624 shares of the mining company’s stock valued at $1,489,509,000 after purchasing an additional 332,797 shares during the last quarter. Hedge funds and other institutional investors own 68.34% of the company’s stock.

Wall Street Analyst Weigh In A number of analysts recently issued reports on AEM shares. Barclays decreased their target price on Agnico Eagle Mines from $210.00 to $188.00 and set an “overweight” rating for the company in a research report on Wednesday, July 15th. Wall Street Zen cut Agnico Eagle Mines from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Bank of America decreased their price objective on Agnico Eagle Mines from $302.00 to $240.00 and set a “buy” rating for the company in a report on Thursday, July 9th. Jefferies Financial Group raised shares of Agnico Eagle Mines from a “hold” rating to a “buy” rating and lifted their target price for the company from $187.00 to $200.00 in a report on Monday, July 6th. Finally, Scotiabank reduced their price target on shares of Agnico Eagle Mines from $278.00 to $260.00 and set a “sector outperform” rating for the company in a research report on Tuesday, July 14th. Twelve investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Agnico Eagle Mines currently has an average rating of “Moderate Buy” and an average target price of $233.62.

Check Out Our Latest Stock Report on Agnico Eagle Mines

Agnico Eagle Mines Stock Performance Shares of AEM stock opened at $136.25 on Tuesday. The stock’s 50-day moving average price is $164.20 and its 200 day moving average price is $191.31. The company has a quick ratio of 2.18, a current ratio of 3.15 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $69.15 billion, a PE ratio of 12.81, a price-to-earnings-growth ratio of 1.82 and a beta of 0.60. Agnico Eagle Mines Limited has a 52-week low of $119.84 and a 52-week high of $255.24.

Agnico Eagle Mines (NYSE:AEM – Get Free Report) (TSE:AEM) last released its earnings results on Thursday, April 30th. The mining company reported $3.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.19 by $0.21. Agnico Eagle Mines had a return on equity of 21.09% and a net margin of 39.46%.The business had revenue of $4 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same quarter in the previous year, the company posted $1.53 earnings per share. The company’s revenue for the quarter was up 66.1% compared to the same quarter last year. As a group, equities research analysts forecast that Agnico Eagle Mines Limited will post 12.29 EPS for the current year.

Agnico Eagle Mines Company Profile (Free Report)

Agnico Eagle Mines Limited (NYSE: AEM) is a Canadian-based senior gold producer headquartered in Toronto, Ontario. The company is principally engaged in the exploration, development, production and reclamation of gold-bearing properties. Agnico Eagle pursues both greenfield and brownfield exploration to expand its resource base and operates a portfolio of producing mines and development projects to generate long-life gold production.

Its core business activities span the full mining lifecycle: grassroots and advanced-stage exploration, prefeasibility and feasibility studies, mine construction, underground and open-pit mining, ore processing and metal recovery, and post-mining reclamation and closure.

Featured Articles Five stocks we like better than Agnico Eagle Mines The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding AEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agnico Eagle Mines Limited (NYSE:AEM – Free Report) (TSE:AEM).

Receive News & Ratings for Agnico Eagle Mines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agnico Eagle Mines and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAndra AP fonden Reduces Position in Lam Research Corporation $LRCX

NEXT HEADLINE »Andra AP fonden Increases Stock Position in Amphenol Corporation $APH

Posted by Defense World Staff on Jul 21st, 2026

Allspring Global Investments Holdings LLC trimmed its holdings in shares of Parker-Hannifin Corporation (NYSE:PH – Free Report) by 19.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,058 shares of the industrial products company’s stock after selling 6,970 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Parker-Hannifin were worth $25,835,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Texas Capital Bancshares Inc TX acquired a new position in Parker-Hannifin in the third quarter valued at about $25,000. HFM Investment Advisors LLC grew its position in shares of Parker-Hannifin by 1,000.0% during the 4th quarter. HFM Investment Advisors LLC now owns 33 shares of the industrial products company’s stock worth $29,000 after buying an additional 30 shares during the period. Lloyd Advisory Services LLC. bought a new stake in shares of Parker-Hannifin in the 4th quarter valued at about $31,000. NFSG Corp increased its stake in shares of Parker-Hannifin by 94.4% in the 1st quarter. NFSG Corp now owns 35 shares of the industrial products company’s stock valued at $31,000 after acquiring an additional 17 shares during the last quarter. Finally, Mowery & Schoenfeld Wealth Management LLC raised its position in shares of Parker-Hannifin by 80.0% in the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 36 shares of the industrial products company’s stock valued at $32,000 after acquiring an additional 16 shares during the period. 82.44% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades A number of research analysts recently issued reports on the stock. Weiss Ratings restated a “buy (b)” rating on shares of Parker-Hannifin in a report on Tuesday, April 21st. Citigroup reiterated a “buy” rating on shares of Parker-Hannifin in a report on Monday, June 8th. Sanford C. Bernstein reissued an “outperform” rating and issued a $1,037.00 price target on shares of Parker-Hannifin in a report on Thursday. Mizuho set a $1,050.00 price objective on shares of Parker-Hannifin in a research report on Friday, May 1st. Finally, JPMorgan Chase & Co. dropped their price objective on Parker-Hannifin from $1,100.00 to $1,060.00 and set an “overweight” rating on the stock in a research note on Thursday, May 7th. Eighteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, Parker-Hannifin presently has a consensus rating of “Moderate Buy” and an average price target of $1,027.38.

Get Our Latest Report on PH

Parker-Hannifin Stock Down 0.3% Parker-Hannifin stock opened at $950.03 on Tuesday. The company has a 50 day moving average of $914.33 and a 200-day moving average of $933.78. The company has a quick ratio of 0.66, a current ratio of 1.13 and a debt-to-equity ratio of 0.46. Parker-Hannifin Corporation has a twelve month low of $692.02 and a twelve month high of $1,034.96. The stock has a market capitalization of $119.79 billion, a PE ratio of 35.04, a price-to-earnings-growth ratio of 2.54 and a beta of 1.11.

Parker-Hannifin (NYSE:PH – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The industrial products company reported $8.17 EPS for the quarter, topping analysts’ consensus estimates of $7.84 by $0.33. Parker-Hannifin had a net margin of 16.58% and a return on equity of 27.97%. The business had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.40 billion. During the same period last year, the business posted $6.94 earnings per share. The firm’s quarterly revenue was up 10.6% on a year-over-year basis. Parker-Hannifin has set its FY 2026 guidance at 31.200-31.200 EPS. On average, equities research analysts anticipate that Parker-Hannifin Corporation will post 31.26 EPS for the current fiscal year.

Parker-Hannifin Increases Dividend The company also recently disclosed a quarterly dividend, which was paid on Friday, June 5th. Investors of record on Friday, May 8th were issued a dividend of $2.00 per share. The ex-dividend date was Friday, May 8th. This is a boost from Parker-Hannifin’s previous quarterly dividend of $1.80. This represents a $8.00 dividend on an annualized basis and a dividend yield of 0.8%. Parker-Hannifin’s dividend payout ratio is 29.51%.

About Parker-Hannifin (Free Report)

Parker-Hannifin Corporation (NYSE: PH) is a global manufacturer and provider of motion and control technologies and systems. The company designs, manufactures and services a broad range of engineered components and systems used to control the movement and flow of liquids, gases and hydraulic power. Its product portfolio is applied across demanding environments and includes solutions for industrial manufacturing, aerospace, mobile equipment and other engineered applications.

Parker-Hannifin’s product and service offerings span hydraulic and pneumatic components, fittings and fluid connectors, valves, pumps and motors, electromechanical actuators and motion-control systems, filtration and separation products, and seals and sealing systems.

Further Reading Five stocks we like better than Parker-Hannifin The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for Parker-Hannifin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parker-Hannifin and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAllspring Global Investments Holdings LLC Sells 19,057 Shares of DTE Energy Company $DTE

NEXT HEADLINE »Allspring Global Investments Holdings LLC Raises Stake in Pattern Group Inc. $PTRN

For nearly two years, the knock on Apple (NASDAQ:AAPL | AAPL Price Prediction) was that it had fallen behind in artificial intelligence. A single approval out of Beijing just complicated that story, and it may vindicate one of Tim Cook’s most contrarian bets on Apple Intelligence China.

China’s Cyberspace Administration has approved Apple Intelligence for launch in China, clearing a regulatory hurdle in place since the feature debuted in 2024. The approval hinges on a partnership integrating Alibaba (NYSE:BABA) and its Qwen model into Apple’s operating systems, with Baidu (NASDAQ:BIDU) confirmed as a development partner.

Markets liked it. Apple shares climbed to a record high on the news, per CNBC’s reporting, driving the Apple stock record high narrative. In Hong Kong trading, Alibaba jumped 5% and Baidu rose 4%.

Why This Approval Mattered So Much Apple Intelligence had been stuck in China since 2024. Chinese rules require AI systems to run on approved domestic models, which is why the Alibaba Qwen and Baidu partnerships unlocked the door.

The stakes are visible. Apple’s Greater China sales hit $20.5 billion in the second quarter of 2026, up 28% year over year. Its share of China’s smartphone market rose to 18.1% from 13.9% a year earlier, according to IDC, helped by iPhone discounts during a recent shopping festival.

[fwp_analyst_ratings symbol=”AAPL” /]

The Tim Cook AI Strategy Everyone Called Risky While Microsoft, Google, Amazon, and Meta poured tens of billions into proprietary frontier models and data centers, Apple declined to join that arms race. It bet on a “model-agnostic” partnership approach, plugging in outside intelligence rather than owning it.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Apple didn't make the cut. Grab the names FREE today.

That looked passive to critics. But the China approval shows the upside. By partnering with Alibaba and Baidu, Apple met local regulatory requirements almost automatically. The same playbook is visible at home: Apple struck a multi-year deal to use Google’s Gemini to help power its revamped Siri, expected to launch in September, running in part on Google Cloud and Nvidia chips.

[fwp_price_target symbol=”AAPL” /]

Why the “Risky” Bet May Be Genius Cook’s strategy lets Apple wear different AI engines in different regulatory regimes without carrying the compute burden itself. Google’s Gemini powers the experience in the United States. Alibaba’s Qwen and Baidu handle China. Apple supplies the device, operating system, and distribution to more than 2.5 billion active devices.

As AI infrastructure costs balloon industry-wide, that capital-light model looks less like a weakness and more like a structural advantage. Rivals own the compute. Apple owns the customer.

The Case for Restraint This is one milestone in one market, well short of a finish line. No firm launch date for Apple Intelligence in China has been announced, so execution risk is real. Apple is also navigating a trade-secrets lawsuit against OpenAI, and it still trails Huawei, which remains the top smartphone seller in its home market of China.

[fwp_price_scenario symbol=”AAPL” /]

A strategy that looked like Apple sitting out the AI race now looks like a deliberate, capital-efficient way to run it. Whether it becomes a durable advantage depends on execution Apple has not yet delivered. For a “final bet” that Wall Street spent two years doubting, Tim Cook just got meaningful validation.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Apple didn't make the cut. Grab the names FREE today.

Contact [email protected] for any questions or corrections.

Aeris Resources Ltd (ASX:AIS, OTC:ARSRF) has more than quadrupled Ore Reserves at its Tritton Operations in central New South Wales, strengthening the foundation for a long-life, multi-mine copper hub centred on the project’s existing processing infrastructure.

Tritton’s Ore Reserve now stands at 10 million tonnes grading 1.7% copper, 0.38 g/t gold and 10 g/t silver, containing around 180,000 tonnes of copper, 130,000 ounces of gold and 3.2 million ounces of silver.

This compares with just 37,000 tonnes of contained copper in the previous reserve estimate and represents more than five years of mill feed at the operation’s current processing capacity.

Mineral Resources have also increased by 70% to 33 million tonnes at 1.7% copper, 0.32 g/t gold and 9 g/t silver, containing approximately 540,000 tonnes of copper. 

Constellation and Mallee Bull drive reserve growth Maiden underground Ore Reserves led the reserve expansion at the Constellation and Mallee Bull deposits.

Constellation contributed 3.8 million tonnes containing about 62,000 tonnes of copper, complementing its existing open-pit reserve and supporting the potential for a longer-life mining operation.

Mallee Bull added a maiden reserve of 2.7 million tonnes at 2.4% copper, containing around 66,000 tonnes of copper. The deposit was added to Aeris’ portfolio through the acquisition of Peel Mining Ltd (ASX:PEX), alongside the Wirlong deposit.

Together, Mallee Bull and Wirlong contributed about 200,000 tonnes of contained copper to Tritton’s Mineral Resource inventory, including roughly 160,000 tonnes classified in the higher-confidence indicated category.

Aeris executive chair André Labuschagne said the enlarged inventory had established “a strong foundation for a long-life, multi-mine copper operation” centred on the Tritton processing plant.

Exploration delivers organic growth Aeris also recorded material resource growth at Avoca Tank and Budgerygar after tripling underground diamond drilling during FY26.

The Avoca Tank Mineral Resource increased by 180% as drilling extended high-grade mineralisation at depth and along strike.

Budgerygar’s Ore Reserve increased by 317% after mining depletion compared with December 2024, reflecting successful resource conversion drilling and mine planning.

Nine of Tritton’s 10 known deposits remain open down-dip, supporting further exploration potential. Aeris plans around 85,000 metres of underground drilling across the operation during FY27.

Updated mine plan ahead The revised Mineral Resources and Ore Reserves will feed into an updated life-of-mine plan and production target for Tritton, expected in the first half of FY27.

At Mallee Bull, Aeris will continue optimising the mine plan and production schedule while advancing feasibility studies, ore transport assessments, permitting work and planning for an exploration decline.

Further drilling at Constellation will target conversion of inferred resources, while metallurgical test work will examine opportunities to improve oxide recoveries and potentially bring production forward.

About Aeris Resources Aeris Resources is an Australian mid-tier copper and gold producer operating the Tritton Copper Operations in New South Wales and the Cracow Gold Operations in Queensland.

The company also holds a pipeline of development and exploration assets and is pursuing a hub-and-spoke strategy at Tritton, using established processing infrastructure to support multiple surrounding ore sources.

Posted by Defense World Staff on Jul 21st, 2026

Andra AP fonden increased its position in shares of Oracle Corporation (NYSE:ORCL – Free Report) by 85.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 224,586 shares of the enterprise software provider’s stock after buying an additional 103,374 shares during the quarter. Andra AP fonden’s holdings in Oracle were worth $33,039,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. HFM Investment Advisors LLC grew its holdings in shares of Oracle by 290.9% during the fourth quarter. HFM Investment Advisors LLC now owns 129 shares of the enterprise software provider’s stock valued at $25,000 after buying an additional 96 shares during the last quarter. Basepoint Wealth LLC acquired a new stake in shares of Oracle in the 4th quarter worth about $26,000. FSA Wealth Management LLC bought a new position in Oracle in the 3rd quarter valued at about $28,000. Osbon Capital Management LLC acquired a new position in Oracle during the 4th quarter valued at about $28,000. Finally, Joseph Group Capital Management acquired a new position in Oracle during the 4th quarter valued at about $29,000. Institutional investors own 42.44% of the company’s stock.

Oracle News Roundup Here are the key news stories impacting Oracle this week:

Negative Sentiment: CLSA initiated coverage on Oracle with a Hold rating and a $145 price target, warning that the company’s AI cloud expansion could require hundreds of billions of dollars in investment and may be difficult to fund without significant borrowing. Article title Negative Sentiment: Multiple reports say Oracle is falling on concerns about rising debt, massive AI infrastructure capex, and potential credit risk linked to large AI customers such as OpenAI, reinforcing fears that the company’s growth strategy could pressure profitability and balance-sheet flexibility. Article title Negative Sentiment: Investors are also reacting to Oracle’s recent credit downgrade toward junk territory and the broader selloff in the stock, which has highlighted execution risk despite the company’s large backlog and AI demand narrative. Article title Neutral Sentiment: Oracle also announced a partnership with IMSA Labs and launched an Oracle Cloud Innovation Studio, showing continued efforts to expand its AI and cloud ecosystem, though this news is not strong enough to offset the current sentiment drag. Article title Insider Activity In related news, Vice Chairman Jeffrey Henley sold 400,000 shares of Oracle stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $159.16, for a total value of $63,664,000.00. Following the sale, the insider owned 400,000 shares of the company’s stock, valued at approximately $63,664,000. The trade was a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 40.90% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In Several analysts have recently commented on ORCL shares. TD Cowen increased their price objective on Oracle from $250.00 to $300.00 and gave the stock a “buy” rating in a research note on Monday, June 8th. Oppenheimer upped their price target on Oracle from $235.00 to $275.00 and gave the stock an “outperform” rating in a report on Monday, June 8th. Barclays increased their price target on Oracle from $240.00 to $250.00 and gave the company an “overweight” rating in a research report on Thursday, June 11th. Moffett Nathanson set a $325.00 price objective on Oracle in a research note on Thursday, June 11th. Finally, Weiss Ratings raised shares of Oracle from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, May 29th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-eight have assigned a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $265.03.

Read Our Latest Stock Analysis on Oracle

Oracle Stock Performance Shares of Oracle stock opened at $121.38 on Tuesday. The business’s fifty day simple moving average is $175.85 and its 200 day simple moving average is $168.74. The company has a current ratio of 1.12, a quick ratio of 1.12 and a debt-to-equity ratio of 3.21. Oracle Corporation has a 12 month low of $120.03 and a 12 month high of $345.72. The firm has a market capitalization of $349.63 billion, a P/E ratio of 20.82, a price-to-earnings-growth ratio of 0.79 and a beta of 1.72.

Oracle (NYSE:ORCL – Get Free Report) last announced its earnings results on Wednesday, June 10th. The enterprise software provider reported $2.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.15. The firm had revenue of $19.18 billion during the quarter, compared to analyst estimates of $19.10 billion. Oracle had a return on equity of 58.62% and a net margin of 25.37%.The business’s revenue was up 20.6% compared to the same quarter last year. During the same period last year, the firm posted $1.70 EPS. Oracle has set its Q1 2027 guidance at 1.720-1.760 EPS and its FY 2027 guidance at 8.050-8.050 EPS. As a group, analysts anticipate that Oracle Corporation will post 6.47 EPS for the current year.

Oracle Dividend Announcement The business also recently announced a quarterly dividend, which will be paid on Friday, July 24th. Stockholders of record on Friday, July 10th will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.6%. The ex-dividend date of this dividend is Friday, July 10th. Oracle’s dividend payout ratio is currently 34.31%.

About Oracle (Free Report)

Oracle Corporation is a multinational technology company that develops and sells database software, cloud engineered systems, enterprise software applications and related services. The company is widely known for its flagship Oracle Database and a portfolio of enterprise-grade software products that support data management, application development, analytics and middleware. Over recent years Oracle has expanded its focus to include cloud infrastructure and cloud applications, positioning itself as a provider of both platform and software-as-a-service solutions for large organizations.

Oracle’s product and service offerings include Oracle Database and the Autonomous Database, Oracle Cloud Infrastructure (OCI), enterprise resource planning (ERP), human capital management (HCM) and supply chain management (SCM) cloud applications (often grouped under Oracle Fusion Cloud Applications), middleware such as WebLogic, and developer technologies including Java and MySQL.

Featured Articles Five stocks we like better than Oracle The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding ORCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oracle Corporation (NYSE:ORCL – Free Report).

Receive News & Ratings for Oracle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oracle and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAndra AP fonden Grows Stock Holdings in Linde PLC $LIN

NEXT HEADLINE »Andra AP fonden Sells 55,555 Shares of The TJX Companies, Inc. $TJX

Posted by Defense World Staff on Jul 21st, 2026

Andra AP fonden raised its position in shares of Wells Fargo & Company (NYSE:WFC – Free Report) by 11.4% in the first quarter, according to its most recent filing with the SEC. The firm owned 439,700 shares of the financial services provider’s stock after purchasing an additional 44,900 shares during the quarter. Andra AP fonden’s holdings in Wells Fargo & Company were worth $35,005,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Diversified Trust Co. raised its position in Wells Fargo & Company by 59.7% in the 4th quarter. Diversified Trust Co. now owns 35,285 shares of the financial services provider’s stock valued at $3,289,000 after buying an additional 13,196 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Wells Fargo & Company by 19.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 532,300 shares of the financial services provider’s stock worth $49,610,000 after acquiring an additional 84,902 shares during the last quarter. Swiss Life Asset Management Ltd grew its stake in shares of Wells Fargo & Company by 4.2% in the 4th quarter. Swiss Life Asset Management Ltd now owns 350,567 shares of the financial services provider’s stock worth $32,673,000 after acquiring an additional 14,168 shares in the last quarter. Vanguard Personalized Indexing Management LLC grew its stake in shares of Wells Fargo & Company by 4.4% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 412,511 shares of the financial services provider’s stock worth $38,446,000 after acquiring an additional 17,302 shares in the last quarter. Finally, Winning Points Advisors LLC purchased a new stake in shares of Wells Fargo & Company in the fourth quarter valued at about $3,384,000. Institutional investors and hedge funds own 75.90% of the company’s stock.

Wells Fargo & Company Stock Performance NYSE WFC opened at $86.24 on Tuesday. The firm has a market cap of $263.90 billion, a P/E ratio of 12.53, a price-to-earnings-growth ratio of 0.96 and a beta of 0.92. The company has a quick ratio of 0.90, a current ratio of 0.90 and a debt-to-equity ratio of 1.09. The company’s 50 day moving average is $81.70 and its 200-day moving average is $83.63. Wells Fargo & Company has a 12-month low of $72.78 and a 12-month high of $97.76.

Wells Fargo & Company Announces Dividend The business also recently declared a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 8th were given a $0.45 dividend. The ex-dividend date was Friday, May 8th. This represents a $1.80 annualized dividend and a dividend yield of 2.1%. Wells Fargo & Company’s payout ratio is 26.16%.

Analyst Ratings Changes A number of equities research analysts have issued reports on the stock. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Wells Fargo & Company in a research report on Friday. Jefferies Financial Group initiated coverage on Wells Fargo & Company in a research note on Thursday, March 26th. They issued a “buy” rating and a $100.00 price objective for the company. Wall Street Zen upgraded Wells Fargo & Company from a “sell” rating to a “hold” rating in a research note on Sunday, June 14th. Phillip Securities upgraded shares of Wells Fargo & Company from a “moderate buy” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Finally, UBS Group lowered their price objective on shares of Wells Fargo & Company from $105.00 to $104.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $98.50.

Read Our Latest Research Report on WFC

Wells Fargo & Company Profile (Free Report)

Wells Fargo & Company is a diversified, U.S.-based financial services company headquartered in San Francisco, California. Founded in 1852 by Henry Wells and William G. Fargo, the firm has evolved from its origins in express delivery and pioneer-era banking into one of the largest full-service banks in the United States. The company provides a broad range of financial products and services to individual, small business, commercial, and institutional clients. Charles W. Scharf serves as chief executive officer.

Wells Fargo operates across several core business segments, including consumer banking and lending, commercial banking, corporate and investment banking, and wealth and investment management.

Recommended Stories Five stocks we like better than Wells Fargo & Company The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for Wells Fargo & Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wells Fargo & Company and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAndra AP fonden Sells 55,555 Shares of The TJX Companies, Inc. $TJX

NEXT HEADLINE »Andra AP fonden Grows Position in PepsiCo, Inc. $PEP

21.7.2026 13:29, MMM

Americký průmyslový konglomerát 3M zveřejnil hospodářské výsledky za druhé čtvrtletí roku 2026. Očištěný zisk na akcii překonal odhady analytiků a společnost zároveň zvýšila celoroční výhled očištěného zisku na akcii i organického růstu tržeb.

Výsledky společnosti 3M (MMM) za 2Q 2026   2Q 2026 Konsensus 2Q 2026 2Q 2025 Tržby (mld. USD) 6,50 6,40 6,34 Čistý zisk (mld. USD) 0,93 -- 0,72 Očištěný zisk na akcii (EPS, USD/akcie) 2,40 2,25 2,16 Výsledky za 2Q Tržby meziročně vzrostly o 2,4 % na 6,5 mld. USD. Očištěné tržby, které nezahrnují vyráběné PFAS produkty, vzrostly o 5,5 % na 6,5 mld. USD, přičemž organický růst dosáhl 5,4 %.

Očištěná provozní marže dosáhla 24,9 %, což je nad odhadem 24,7 % a zároveň nárůst o 40 bazických bodů oproti loňským 24,5 %. Provozní marže činila 15,1 %, meziročně pokles o 290 bazických bodů.

Tržby podle segmentů, zdroj: 3M

Provozní hotovostní tok dosáhl 1 mld. USD, nad odhadem 777,8 mil. USD. Očištěný volný hotovostní tok činil 1,3 mld. USD.

Výhled na FY 2026 Firma zvýšila výhled pro celý rok 2026 a nyní predikuje:

Očištěný zisk na akcii 8,80–8,95 USD (dříve: 8,50–8,70 USD). Organický růst tržeb nad 3,5 % (dříve: přibližně 3 %). Očištěný celkový růst tržeb nad 4,5 %. Očištěný provozní hotovostní tok 5,8–6 mld. USD. Rozšíření očištěné provozní marže o 70 až 80 bazických bodů. Výhled zatím nezohledňuje akvizici společnosti Madison Fire & Rescue, která byla dokončena 1. července.

Komentář vedení William Brown, předseda představenstva a generální ředitel 3M, uvedl: „Zaznamenali jsme silné druhé čtvrtletí, kdy jsme překonali očekávání díky růstu tržeb ve středních jednociferných číslech, solidní provozní marži kolem 25 % a dvouciferným růstem zisku na akcii, což odráží pokrok, kterého dosahujeme v našich strategických prioritách a při budování výkonnější společnosti. V důsledku silné výkonnosti v první polovině roku a pokračující dynamiky zvyšujeme celoroční výhled a zůstáváme přesvědčeni o naší schopnosti dlouhodobě vytvářet hodnotu pro akcionáře.“

Návrat kapitálu akcionářům Společnost za čtvrtletí vrátila akcionářům celkem 1,4 mld. USD formou dividend a zpětných odkupů akcií.

Akcie 3M Akcie 3M (MMM) v předburzovní fázi obchodování rostou o 6,22 % na 169 USD.

Akcie 3M Co (MMM) před výsledky uzavřely na 159,11 USD Ukazatel   Ukazatel   Kapitalizace (mld. USD) 83,0 P/E 17,4 Vývoj za letošní rok (%) -0,6 Očekávané P/E 18,2 52týdenní minimum (USD) 139,3 Prům. cílová cena (USD) 174,9 52týdenní maximum (USD) 177,4 Dividendový výnos (%) 1,9 Zdroj: 3M, Bloomberg

Michal Šnobl, Fio banka, a.s.

Posted by Defense World Staff on Jul 21st, 2026

Andra AP fonden decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 53.9% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 222,601 shares of the biopharmaceutical company’s stock after selling 260,199 shares during the period. Andra AP fonden’s holdings in Gilead Sciences were worth $31,024,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Strategic Investment Solutions Inc. IL acquired a new position in shares of Gilead Sciences during the 4th quarter worth about $25,000. Vermillion & White Wealth Management Group LLC increased its position in shares of Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 85 shares during the last quarter. Quattro Advisors LLC bought a new stake in Gilead Sciences during the fourth quarter worth about $26,000. Wealth Preservation Advisors LLC raised its holdings in Gilead Sciences by 60.0% during the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 81 shares in the last quarter. Finally, Ares Financial Consulting LLC acquired a new position in Gilead Sciences during the fourth quarter valued at approximately $28,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analysts Set New Price Targets Several research analysts have weighed in on GILD shares. Wall Street Zen raised Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a report on Wednesday, May 20th. Rothschild & Co Redburn decreased their target price on shares of Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Citigroup boosted their target price on shares of Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Finally, Morgan Stanley dropped their price target on shares of Gilead Sciences from $168.00 to $166.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 8th. Twenty-six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $159.04.

Check Out Our Latest Report on GILD

Insider Activity In other news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00. Following the transaction, the insider owned 125,779 shares of the company’s stock, valued at approximately $16,513,524.91. This represents a 18.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the sale, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. The trade was a 1.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 77,000 shares of company stock valued at $9,978,740. 0.30% of the stock is owned by insiders.

Gilead Sciences Price Performance NASDAQ:GILD opened at $133.21 on Tuesday. The company has a market cap of $165.39 billion, a P/E ratio of 18.15 and a beta of 0.32. The firm’s fifty day moving average price is $129.72 and its two-hundred day moving average price is $135.37. Gilead Sciences, Inc. has a one year low of $107.75 and a one year high of $157.29. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. During the same quarter last year, the company posted $1.81 EPS. Gilead Sciences’s quarterly revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities analysts expect that Gilead Sciences, Inc. will post -0.77 earnings per share for the current year.

Gilead Sciences Announces Dividend The company also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Monday, June 15th were issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date was Monday, June 15th. Gilead Sciences’s payout ratio is currently 44.69%.

Gilead Sciences Company Profile (Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Featured Articles Five stocks we like better than Gilead Sciences The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAndra AP fonden Grows Position in PepsiCo, Inc. $PEP

NEXT HEADLINE »Andra AP fonden Purchases 107,689 Shares of Cisco Systems, Inc. $CSCO

Realty Income Corporation remains a compelling buy, combining attractive valuation, quality, and a robust 5.14% yield versus peers. O is executing significant growth, raising 2026 investment guidance to $9.5B and boosting adjusted FFO per share outlook to $4.41–$4.44. The portfolio's defensible retail mix, staggered lease expirations, and low tenant concentration underpin O's low-risk profile.

The multiyear partnership is part of the food conglomerate's effort to reinvigorate its brands.

In a July 21 X post, the famous ‘Big Short’ trader, Michael Burry, drew attention to a study showing that big tech’s overall debt significantly exceeds the fully disclosed figures.

Specifically, the legendary investor highlighted a recent Nikkei Research study that found that just five U.S. technology giants carry as much as $1.65 trillion in so-called ‘hidden debt’ – burden that does not appear on the balance sheet thanks to a wide variety of obfuscating methods. 

The figure is made only more alarming once its growth is taken into account. Indeed, as recently as 2022, the number stood in the low hundreds of billions and has been steadily accelerating, with the 2026 balance anticipated to be roughly twice as high as in 2025.

PALO ALTO, California — Hidden debt at U.S. tech giants swelled eightfold in roughly four years to an estimated $1.65 trillion as artificial intelligence investments ballooned, a Nikkei study shows, exceeding actual debt and making it tougher for investors to assess risk.
Nikkei… pic.twitter.com/SW4eZ1rG1R

— Cassandra Unchained (@michaeljburry) July 21, 2026 Oracle debt soars 30x on OpenAI data center commitment Elsewhere, examining the Nikkei report more closely reveals that Meta’s (NASDAQ: META) off-balance-sheet debt is especially high at $420 billion, while Oracle’s (NYSE: ORCL) has been rising at a particularly rapid rate.

According to the study, Oracle saw its burden soar roughly 30-fold over four years, reaching $273.3 billion by the end of May. 

Notably, the firm might be particularly exposed to any adverse developments in the wider AI space, considering its ability to pay back the debt is mostly reliant on the future profitability and success of OpenAI.

Simultaneously, leaked financials for 2024 and 2025 for Sam Altman’s firm strongly hint that the company might not be able to pay Oracle in time, if at all.

Meanwhile, recent developments showcase both the continued confidence blue-chip technology giants have in the eventual benefits of their vast infrastructure investments and the strain the greater program has put on credit providers.

Alphabet (NASDAQ: GOOGL) – one of the firms included in the $1.65 trillion total – recently made its first equity offering in roughly two decades, raising over $80 billion from Warren Buffett and other investors across the market.

Possible signs of strain are also evident with the last two examined companies – Microsoft (NASDAQ: MSFT) and Amazon (NASDAQ: AMZN) – as both have been undertaking significant layoffs in what some critics speculate are attempts to save cash to facilitate continued CapEx.

As for Michael Burry, the $1.65 trillion in hidden debt for some of the biggest technology firms involved with the ‘AI boom’ appears to back his long-standing thesis that the prevailing situation in the market is unsustainable.

The legendary short trader drew much scrutiny in recent years with his attempts to bet against the semiconductor industry, and his more recent wagers that Nvidia (NASDAQ: NVDA) and Palantir (NASDAQ: PLTR) stocks would experience a decline have, so far, been offering mixed results.

Lastly, the situation might shift once again already in July as nearly all companies included in the study are set to report their quarterly earnings, with the probable continuation of the trend possibly proving especially damaging given that big tech owes much of its popularity to historically being asset-light and cash-heavy.

Featured image via Shutterstock

Best Crypto Exchange for Intermediate Traders and Investors

Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

Copy top-performing traders in real time, automatically.

eToro USA is registered with FINRA for securities trading.

30+ million Users worldwide

eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more.

Join Finbold's newsroom, become a Sales Executive today! Apply now to join Finbold as a crypto/finance news writer!

Posted by Defense World Staff on Jul 21st, 2026

AlTi Global Inc. reduced its position in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 92.0% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 9,221 shares of the biopharmaceutical company’s stock after selling 105,548 shares during the period. AlTi Global Inc.’s holdings in Bristol Myers Squibb were worth $559,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Bristol Myers Squibb by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock worth $10,719,376,000 after buying an additional 2,743,759 shares during the last quarter. State Street Corp increased its stake in shares of Bristol Myers Squibb by 1.4% during the 4th quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company’s stock valued at $5,285,065,000 after acquiring an additional 1,385,206 shares during the last quarter. Geode Capital Management LLC raised its stake in Bristol Myers Squibb by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock worth $2,837,026,000 after purchasing an additional 6,084,046 shares during the period. Norges Bank acquired a new stake in shares of Bristol Myers Squibb during the 4th quarter worth $1,947,272,000. Finally, AQR Capital Management LLC raised its position in shares of Bristol Myers Squibb by 172.6% in the 4th quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock worth $1,391,485,000 after buying an additional 16,332,924 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth BMY has been the subject of a number of research reports. Weiss Ratings downgraded Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $54.00 price objective on shares of Bristol Myers Squibb in a research note on Monday, July 6th. Bank of America decreased their target price on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a report on Friday, July 10th. UBS Group reissued a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Finally, Guggenheim restated a “buy” rating and issued a $72.00 price target on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Eight equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and an average price target of $61.25.

Get Our Latest Stock Analysis on Bristol Myers Squibb

Bristol Myers Squibb Trading Down 0.7% NYSE:BMY opened at $60.30 on Tuesday. The business’s 50-day moving average is $57.11 and its two-hundred day moving average is $57.85. The firm has a market capitalization of $123.14 billion, a PE ratio of 16.94, a price-to-earnings-growth ratio of 0.17 and a beta of 0.23. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $62.89. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.42 by $0.16. The company had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts predict that Bristol Myers Squibb Company will post 6.34 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement The company also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is presently 70.79%.

Key Stories Impacting Bristol Myers Squibb Here are the key news stories impacting Bristol Myers Squibb this week:

Positive Sentiment: Bristol Myers Squibb expanded its NVIDIA partnership and plans to deploy a DGX SuperPOD based on Vera Rubin systems, which the company says will become the most powerful AI factory in life sciences and should enhance drug discovery and development efficiency. Bristol Myers Expands NVIDIA Partnership to Build Top Life Sciences AI Supercomputer Positive Sentiment: The company also said it will be the first life sciences firm to buy Nvidia’s latest DGX SuperPOD system, signaling an aggressive investment in AI infrastructure that could strengthen Bristol Myers’ competitive position in future drug research. Bristol Myers buys Nvidia’s latest AI computing system for drug research Neutral Sentiment: A Reuters report repeated the AI-infrastructure news, reinforcing the strategic nature of the announcement but adding no materially new information for investors. Bristol Myers buys Nvidia’s latest AI computing system for drug research Neutral Sentiment: Bristol Myers was mentioned in a broader article about cancer-drug competition and next-generation therapies, but the piece mainly discussed the market landscape rather than any company-specific development. Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over. Negative Sentiment: Healthcare stocks fell late Monday afternoon, which may be creating a modest drag on BMY and offsetting some of the optimism from the NVIDIA partnership news. Sector Update: Healthcare Stocks Fall Late Afternoon About Bristol Myers Squibb (Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Featured Articles Five stocks we like better than Bristol Myers Squibb The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).

Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEASML Holding N.V. $ASML Shares Sold by AlTi Global Inc.

NEXT HEADLINE »Amova Asset Management Americas Inc. Sells 54,907 Shares of Nu Holdings Ltd. $NU

Posted by Defense World Staff on Jul 21st, 2026

Amova Asset Management Americas Inc. lessened its stake in Roku, Inc. (NASDAQ:ROKU – Free Report) by 37.1% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,848,889 shares of the company’s stock after selling 1,092,615 shares during the quarter. Roku comprises 2.5% of Amova Asset Management Americas Inc.’s investment portfolio, making the stock its 11th biggest position. Amova Asset Management Americas Inc. owned 1.25% of Roku worth $174,923,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Jefferies Financial Group Inc. acquired a new position in shares of Roku during the 4th quarter valued at $1,345,000. Moran Wealth Management LLC acquired a new stake in Roku in the first quarter worth $2,990,000. MH & Associates Securities Management Corp ADV bought a new stake in Roku in the fourth quarter valued at $2,398,000. Katamaran Capital LLP increased its stake in Roku by 90.8% in the first quarter. Katamaran Capital LLP now owns 52,548 shares of the company’s stock valued at $4,972,000 after purchasing an additional 25,002 shares in the last quarter. Finally, Maxi Investments CY Ltd acquired a new position in shares of Roku during the fourth quarter valued at about $1,953,000. Institutional investors own 86.30% of the company’s stock.

Roku Stock Down 0.2% Shares of NASDAQ:ROKU opened at $144.13 on Tuesday. The stock has a market cap of $21.25 billion, a price-to-earnings ratio of 108.37 and a beta of 2.01. Roku, Inc. has a 12-month low of $78.53 and a 12-month high of $148.88. The business’s 50 day moving average is $133.04 and its 200 day moving average is $112.78.

Roku (NASDAQ:ROKU – Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.23. The business had revenue of $1.25 billion during the quarter, compared to the consensus estimate of $1.20 billion. Roku had a return on equity of 7.64% and a net margin of 4.06%.Roku’s revenue was up 22.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.19) earnings per share. As a group, equities research analysts expect that Roku, Inc. will post 2.41 earnings per share for the current year.

Analyst Upgrades and Downgrades A number of research firms have recently issued reports on ROKU. Citigroup increased their price objective on shares of Roku from $120.00 to $157.00 and gave the stock a “neutral” rating in a research report on Friday. Susquehanna downgraded Roku from a “positive” rating to a “neutral” rating and set a $160.00 price target on the stock. in a research note on Tuesday, June 16th. Zacks Research lowered Roku from a “strong-buy” rating to a “hold” rating in a report on Tuesday, April 14th. Morgan Stanley raised their price objective on Roku from $150.00 to $170.00 and gave the company an “overweight” rating in a research note on Thursday, June 4th. Finally, UBS Group set a $160.00 price objective on Roku in a report on Monday, June 15th. Ten research analysts have rated the stock with a Buy rating and seventeen have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $155.12.

Get Our Latest Stock Analysis on ROKU

Insider Activity at Roku In related news, insider Charles Collier sold 20,538 shares of the business’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $124.23, for a total transaction of $2,551,435.74. Following the transaction, the insider directly owned 7,700 shares in the company, valued at approximately $956,571. The trade was a 72.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gilbert Fuchsberg sold 9,593 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $125.52, for a total value of $1,204,113.36. Following the completion of the transaction, the insider owned 50,863 shares in the company, valued at $6,384,323.76. The trade was a 15.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 236,499 shares of company stock valued at $30,582,963 over the last three months. Insiders own 13.45% of the company’s stock.

Roku Profile (Free Report)

Roku, Inc (NASDAQ: ROKU) is a technology company that develops and operates a proprietary streaming platform designed to deliver entertainment content to consumers via internet-connected devices and smart televisions. Since its inception in 2002 in California, Roku has focused on simplifying access to streaming services for viewers worldwide. The company’s platform enables users to discover, access and manage a wide array of over-the-top content from major streaming services, free ad-supported channels and niche providers.

At the core of Roku’s product lineup are a range of streaming players and sticks, which connect to televisions via HDMI and deliver the Roku OS experience.

Further Reading Five stocks we like better than Roku The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding ROKU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roku, Inc. (NASDAQ:ROKU – Free Report).

Receive News & Ratings for Roku Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roku and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINERoyalty Pharma PLC $RPRX Holdings Lowered by AlTi Global Inc.

NEXT HEADLINE »Block, Inc. $XYZ Shares Sold by Amova Asset Management Americas Inc.

Micron Technology (NASDAQ: MU) could face modest downside over the coming days, according to the latest forecast generated by the Finbold AI Agent. 

The machine learning model projects Micron stock to trade at an average price of $849.66 on August 1, 2026, representing a 1.92% decline from its reference price of $866.30.

MU stock price prediction. Source: Finbold The forecast comes after a period of heightened volatility for Micron shares, which have surged on the back of booming artificial intelligence demand and strong pricing across the memory semiconductor market. 

While Wall Street remains broadly bullish on the company’s long-term outlook, the AI-powered prediction suggests MU stock could experience short-term pressure before the start of August.

The Finbold AI Agent aggregates forecasts from multiple large language models and machine learning systems to estimate future price movements. For Micron, the models produced a range of outcomes for August 1.

GPT-5.6 Sol delivered the most optimistic forecast, projecting MU shares at $910, implying a 5.04% gain. Gemini 3.5 Flash predicted a price of $855, while Claude Opus 4.8 forecast $815.20. Grok 4.5 was also cautious, estimating a price target of $818.45.

Combining the individual forecasts resulted in an average projected price of $849.66, suggesting a modest pullback from current levels.

MU stock price prediction. Source: Finbold MU stock fundamentals Despite the near-term bearish forecast, Micron continues to benefit from strong demand for high-bandwidth memory (HBM) and other AI-related memory products.

The company reported record fiscal third-quarter 2026 revenue of $41.46 billion, significantly exceeding analyst expectations. 

Non-GAAP earnings per share reached $25.11, while management issued fourth-quarter revenue guidance of approximately $50 billion, reflecting continued momentum in AI infrastructure spending.

Micron has also stated that its HBM supply for 2026 is fully sold out, with demand visibility extending into 2027. These trends have helped drive one of the strongest stock performances in the semiconductor sector this year.

Micron stock technical indicators  The Finbold AI Agent’s forecast aligns with recent technical weakness in Micron shares. The stock has retreated sharply from its all-time highs, while momentum indicators have softened.

The Relative Strength Index (RSI) has trended lower in recent weeks, indicating fading buying pressure. At the same time, the Moving Average Convergence Divergence (MACD) indicator remains under pressure, reflecting a slowdown in upward momentum following the stock’s rapid advance earlier in the year.

While Micron’s long-term outlook remains supported by AI-driven memory demand, the machine learning forecast suggests investors could see additional short-term volatility before August begins.

Best Crypto Exchange for Intermediate Traders and Investors

Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

Copy top-performing traders in real time, automatically.

eToro USA is registered with FINRA for securities trading.

30+ million Users worldwide

eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more.

Join Finbold's newsroom, become a Sales Executive today! Apply now to join Finbold as a crypto/finance news writer!

Posted by Defense World Staff on Jul 21st, 2026

AlTi Global Inc. grew its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG – Free Report) by 353.2% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,023 shares of the medical equipment provider’s stock after purchasing an additional 2,356 shares during the quarter. AlTi Global Inc.’s holdings in Intuitive Surgical were worth $1,394,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Fiduciary Financial Group LLC boosted its position in shares of Intuitive Surgical by 2.1% in the fourth quarter. Fiduciary Financial Group LLC now owns 920 shares of the medical equipment provider’s stock worth $521,000 after purchasing an additional 19 shares during the period. Prosperity Consulting Group LLC raised its position in shares of Intuitive Surgical by 0.5% during the 3rd quarter. Prosperity Consulting Group LLC now owns 4,033 shares of the medical equipment provider’s stock valued at $1,804,000 after purchasing an additional 19 shares during the period. Sunburst Financial Group LLC lifted its stake in shares of Intuitive Surgical by 4.3% during the 4th quarter. Sunburst Financial Group LLC now owns 485 shares of the medical equipment provider’s stock valued at $275,000 after buying an additional 20 shares in the last quarter. WoodTrust Financial Corp boosted its holdings in Intuitive Surgical by 0.5% in the 4th quarter. WoodTrust Financial Corp now owns 4,180 shares of the medical equipment provider’s stock worth $2,367,000 after buying an additional 20 shares during the period. Finally, North Star Investment Management Corp. boosted its holdings in Intuitive Surgical by 8.5% in the 4th quarter. North Star Investment Management Corp. now owns 269 shares of the medical equipment provider’s stock worth $152,000 after buying an additional 21 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Wall Street Analyst Weigh In A number of research firms have commented on ISRG. Raymond James Financial reissued an “outperform” rating and set a $483.00 price target (down from $577.00) on shares of Intuitive Surgical in a report on Friday. BMO Capital Markets reissued an “outperform” rating on shares of Intuitive Surgical in a research note on Monday. Robert W. Baird lowered their price target on Intuitive Surgical from $525.00 to $500.00 and set an “outperform” rating on the stock in a report on Friday. Weiss Ratings restated a “hold (c)” rating on shares of Intuitive Surgical in a research note on Tuesday, May 19th. Finally, Evercore set a $430.00 price objective on shares of Intuitive Surgical in a report on Monday, July 6th. Twenty-one analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $523.46.

Read Our Latest Research Report on Intuitive Surgical

Intuitive Surgical Stock Performance NASDAQ:ISRG opened at $353.17 on Tuesday. The firm has a market capitalization of $125.08 billion, a PE ratio of 40.45, a PEG ratio of 2.80 and a beta of 1.46. The stock’s fifty day moving average is $413.94 and its 200 day moving average is $465.58. Intuitive Surgical, Inc. has a fifty-two week low of $342.10 and a fifty-two week high of $603.88.

Intuitive Surgical (NASDAQ:ISRG – Get Free Report) last posted its quarterly earnings data on Tuesday, April 21st. The medical equipment provider reported $2.50 EPS for the quarter, topping the consensus estimate of $2.08 by $0.42. Intuitive Surgical had a net margin of 28.45% and a return on equity of 17.09%. The company had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.62 billion. During the same period in the previous year, the firm earned $1.81 earnings per share. Intuitive Surgical’s quarterly revenue was up 23.0% compared to the same quarter last year. Equities analysts forecast that Intuitive Surgical, Inc. will post 8.62 EPS for the current year.

Insider Activity at Intuitive Surgical In related news, SVP Iman Jeddi sold 5,625 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $420.55, for a total value of $2,365,593.75. Following the sale, the senior vice president directly owned 6,463 shares of the company’s stock, valued at $2,718,014.65. This represents a 46.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Gary Loeb sold 400 shares of the stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $424.14, for a total value of $169,656.00. Following the completion of the sale, the executive vice president owned 5,720 shares in the company, valued at approximately $2,426,080.80. The trade was a 6.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 7,169 shares of company stock worth $3,059,135. Insiders own 0.60% of the company’s stock.

Key Intuitive Surgical News Here are the key news stories impacting Intuitive Surgical this week:

Positive Sentiment: Some market commentary argues ISRG’s recent correction may have reset expectations, with oversold technical conditions and improving earnings estimate revisions potentially setting up a near-term rebound. Down 15% in 4 Weeks, Here’s Why You Should You Buy the Dip in Intuitive Surgical (ISRG) Positive Sentiment: Zacks highlighted Intuitive Surgical as a trending stock with strong growth characteristics, saying the company’s fundamentals and growth profile may appeal to investors looking for long-term outperformance. 3 Reasons Growth Investors Will Love Intuitive Surgical (ISRG) Positive Sentiment: Another piece noted investor interest in ISRG remains elevated, suggesting the stock is staying on traders’ radar even after recent weakness. Intuitive Surgical, Inc. (ISRG) Is a Trending Stock: Facts to Know Before Betting on It Neutral Sentiment: Commentary focused on whether investors should prioritize Intuitive Surgical’s current robot sales or its longer-term growth opportunity, reinforcing the debate around valuation versus future expansion. What’s More Important For Intuitive Surgical: Today’s Robots Or Tomorrow’s Growth? Negative Sentiment: Several analyst updates were cautious, with firms including Stifel, Sanford C. Bernstein, and Citigroup lowering price targets or expectations, which likely added to the selling pressure on ISRG. Stifel Nicolaus Lowers Intuitive Surgical (NASDAQ:ISRG) Price Target to $550.00 About Intuitive Surgical (Free Report)

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.

See Also Five stocks we like better than Intuitive Surgical The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for Intuitive Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intuitive Surgical and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAlTi Global Inc. Purchases New Holdings in Grayscale Bitcoin Mini Trust ETF $BTC

NEXT HEADLINE »Amova Asset Management Americas Inc. Sells 4,933 Shares of MercadoLibre, Inc. $MELI

A securities fraud class action lawsuit has been filed on behalf of Zillow investors after its stock plummeted over 16% because of Zillow's alleged anticompetitive agreement with Redfin, potentially violating federal securities laws.

, /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Zillow Group, Inc. (NASDAQ:Z, ZG) and certain of the Company's senior executives for securities fraud after significant stock drops resulting from potential violations of the federal securities laws.

If you invested in Zillow, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/zillow-class-action-lawsuit.

Key Details of the Zillow ($Z, $ZG) Class Action:

Lead Plaintiff Deadline: August 10, 2026 Alleged Misconduct: Securities fraud relating to Zillow's allegedly anticompetitive agreement with Redfin Corporation Largest Alleged Stock Drop: February 11, 2026 – 16.54% Stock Drop on Class C shares; 17.13% Stock Drop on Class A shares. Court: U.S. District Court for the Western District of Washington Action: Contact BFA Law to discuss your rights Investors have until August 10, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Zillow Class C and Class A common stock. The class action is pending in the U.S. District Court for the Western District of Washington. It is captioned Breidert v. Zillow Group, Inc., et al., No. 26-cv-02016.

Why is Zillow Being Sued for Securities Fraud?

On February 6, 2025, Zillow entered into an agreement with Redfin through which Zillow became the exclusive provider of multifamily rental listings on Redfin's platform and affiliate websites, including Rent.com. According to the complaint, during the relevant period, Zillow characterized the agreement with Redfin as a "partnership" that would provide Zillow exclusive access to Redfin's advertising platform.

As alleged, in truth, under the terms of the agreement, Zillow paid Redfin $100 million to stop competing with Zillow, facilitate the transition of its multifamily rental advertising business to Zillow, and close the remainder of its business. 

Why did Zillow's Stock Drop?

On September 30, 2025, the FTC filed a complaint against Zillow and Redfin alleging violations of the federal antitrust laws. According to the FTC complaint, "Zillow and Redfin executed an unlawful agreement to remove competition from [the online rental marketplaces industry], starting with a $100 million payment to Redfin to exit the [Internet Listing Services] market." In sum, the FTC alleged, "[t]his agreement is nothing more than an end run around competition on the merits with Redfin for customers…" This news caused the price of Zillow's Class C and A common stock to decline 4.33% and 4.5%, respectively.

On February 10, 2026, Zillow's CFO told investors that Zillow experienced increased legal expenses which "will result in approximately 200 basis points headwind to EBITDA margins in Q1." On this news, the price of Zillow's Class C and A common stock declined 16.54%, and 17.13%, respectively.

Finally, on May 7, 2026, Reuters reported that a "federal judge rejected [Zillow and Redfin's] request to end a [FTC] lawsuit accusing them of illegally agreeing to suppress competition for online apartment rental listings." This news caused the price of Zillow's Class C and A common stock to decline 1.9% and 1.76%, respectively.

Click here for more information: https://www.bfalaw.com/cases/zillow-class-action-lawsuit.

What Can You Do?

If you invested in Zillow, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/zillow-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, "Litigation Stars" by Benchmark Litigation, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff's securities litigation law firm, with clients noting: "[t]here is no better service provider in the practice area," "[t]he interest of the client is always front and center," and "[t]here isn't a better firm in this space." One testimonial described the firm as "nimble and entrepreneurial," with a "relentless focus on adding value for clients."

Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/zillow-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

SOURCE Bleichmar Fonti & Auld LLP

Posted by Defense World Staff on Jul 21st, 2026

AlTi Global Inc. boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 312.7% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,857 shares of the biopharmaceutical company’s stock after purchasing an additional 1,407 shares during the period. AlTi Global Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,435,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Nordea Investment Management AB increased its position in shares of Regeneron Pharmaceuticals by 118.1% in the fourth quarter. Nordea Investment Management AB now owns 137,321 shares of the biopharmaceutical company’s stock worth $105,810,000 after acquiring an additional 74,350 shares in the last quarter. Lockheed Martin Investment Management Co. purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $2,702,000. Asio Capital LLC acquired a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $3,422,000. Robeco Institutional Asset Management B.V. boosted its stake in Regeneron Pharmaceuticals by 116.6% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 261,850 shares of the biopharmaceutical company’s stock worth $202,114,000 after purchasing an additional 140,966 shares during the period. Finally, National Pension Service grew its position in Regeneron Pharmaceuticals by 29.8% during the 4th quarter. National Pension Service now owns 360,988 shares of the biopharmaceutical company’s stock worth $278,636,000 after purchasing an additional 82,853 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling at Regeneron Pharmaceuticals In related news, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. This represents a 1.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.7% Shares of NASDAQ:REGN opened at $672.15 on Tuesday. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $71.06 billion, a PE ratio of 16.38, a P/E/G ratio of 1.50 and a beta of 0.24. Regeneron Pharmaceuticals, Inc. has a 1 year low of $541.00 and a 1 year high of $821.11. The firm has a fifty day moving average price of $640.18 and a 200 day moving average price of $717.26.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last posted its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating the consensus estimate of $8.91 by $0.56. The company had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business’s revenue was up 19.0% compared to the same quarter last year. During the same period last year, the company earned $8.22 earnings per share. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.12 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.

Wall Street Analyst Weigh In A number of analysts have recently issued reports on REGN shares. HSBC reduced their target price on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a report on Monday, July 6th. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. Royal Bank Of Canada decreased their price objective on Regeneron Pharmaceuticals from $707.00 to $696.00 and set a “sector perform” rating for the company in a research report on Tuesday, July 7th. Canaccord Genuity Group lowered their target price on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Finally, Sanford C. Bernstein reduced their price target on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a research report on Wednesday, April 8th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $787.67.

View Our Latest Analysis on Regeneron Pharmaceuticals

Key Stories Impacting Regeneron Pharmaceuticals Here are the key news stories impacting Regeneron Pharmaceuticals this week:

Negative Sentiment: Multiple law firms, including Bernstein Liebhard, Levi & Korsinsky, the Schall Law Firm, the DJS Law Group, Faruqi & Faruqi, and Bronstein, Gewirtz & Grossman, announced or reminded investors about a class action lawsuit against Regeneron Pharmaceuticals, Inc. (REGN), with a lead plaintiff deadline of September 14, 2026. These notices suggest potential litigation risk and uncertainty for shareholders. Article Title Negative Sentiment: The lawsuit coverage increases headline risk and could weigh on sentiment until more details emerge about the alleged claims and the company’s response. Article Title Neutral Sentiment: The company previously reported strong quarterly results, including earnings and revenue that beat expectations, which remains a supportive backdrop for the stock even as legal issues dominate near-term trading. MarketBeat Regeneron Pharmaceuticals Profile (Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

See Also Five stocks we like better than Regeneron Pharmaceuticals The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAlTi Global Inc. Makes New Investment in Establishment Labs Holdings Inc. $ESTA

NEXT HEADLINE »AlTi Global Inc. Has $1.14 Million Holdings in Paramount Skydance Corporation $PSKY

Posted by Defense World Staff on Jul 21st, 2026

Amova Asset Management Americas Inc. lowered its position in shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM – Free Report) by 12.5% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 312,975 shares of the semiconductor company’s stock after selling 44,653 shares during the quarter. Taiwan Semiconductor Manufacturing makes up about 1.5% of Amova Asset Management Americas Inc.’s investment portfolio, making the stock its 19th largest position. Amova Asset Management Americas Inc.’s holdings in Taiwan Semiconductor Manufacturing were worth $105,782,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in TSM. Quattro Advisors LLC bought a new stake in shares of Taiwan Semiconductor Manufacturing during the fourth quarter worth approximately $25,000. Hilton Head Capital Partners LLC bought a new position in Taiwan Semiconductor Manufacturing in the fourth quarter valued at approximately $27,000. Stephens Consulting LLC grew its holdings in Taiwan Semiconductor Manufacturing by 82.0% during the 4th quarter. Stephens Consulting LLC now owns 91 shares of the semiconductor company’s stock worth $28,000 after acquiring an additional 41 shares during the period. Strategic Advocates LLC grew its holdings in Taiwan Semiconductor Manufacturing by 62.1% during the 4th quarter. Strategic Advocates LLC now owns 94 shares of the semiconductor company’s stock worth $28,000 after acquiring an additional 36 shares during the period. Finally, Ares Financial Consulting LLC bought a new stake in shares of Taiwan Semiconductor Manufacturing during the 4th quarter valued at $29,000. Institutional investors and hedge funds own 16.51% of the company’s stock.

More Taiwan Semiconductor Manufacturing News Here are the key news stories impacting Taiwan Semiconductor Manufacturing this week:

Positive Sentiment: TSMC reported record second-quarter results, with revenue growth, strong margins, and raised full-year guidance, reinforcing that AI chip demand remains robust. Positive Sentiment: Several bullish commentaries and analyst notes argue the post-earnings pullback may be a buying opportunity, citing sustained AI-driven growth and expanding leading-edge production. Positive Sentiment: The company said demand for AI chips should stay strong for years, and its expanded Arizona investment underscores confidence in long-term capacity needs and customer demand. Reuters article on AI demand and Arizona investment Positive Sentiment: Coverage citing billionaire investors and “AI capex winners” has kept TSMC in the spotlight as one of the clearest beneficiaries of the AI buildout. Neutral Sentiment: Some articles frame the move as a valuation and positioning reset after a strong run, suggesting part of the recent weakness may reflect profits being taken rather than a change in fundamentals. Seeking Alpha article on what was priced in Negative Sentiment: Investors are worried the extra $100 billion Arizona plan could pressure near-term profit margins, especially with construction labor and infrastructure constraints. Negative Sentiment: Broader semiconductor weakness and bear-market concerns in the sector are also weighing on sentiment, even though TSMC’s own results remain strong. Insider Buying and Selling at Taiwan Semiconductor Manufacturing In related news, VP Bor-Zen Tien purchased 2,000 shares of the business’s stock in a transaction on Tuesday, May 19th. The shares were purchased at an average price of $69.91 per share, with a total value of $139,820.00. Following the completion of the purchase, the vice president owned 11,051 shares in the company, valued at $772,575.41. This represents a 22.10% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Tzu-Sou Chuang sold 200,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $69.83, for a total transaction of $13,966,000.00. Following the completion of the transaction, the vice president owned 2,495,165 shares of the company’s stock, valued at $174,237,371.95. This trade represents a 7.42% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have purchased 6,857 shares of company stock valued at $512,334. 1.11% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes A number of research firms have recently weighed in on TSM. Barclays increased their price target on Taiwan Semiconductor Manufacturing from $625.00 to $650.00 and gave the company an “overweight” rating in a research note on Friday. TD Cowen increased their target price on Taiwan Semiconductor Manufacturing from $400.00 to $440.00 and gave the company a “hold” rating in a research note on Friday. Needham & Company LLC raised their target price on Taiwan Semiconductor Manufacturing from $410.00 to $480.00 and gave the stock a “buy” rating in a report on Thursday, April 16th. Citigroup restated a “buy” rating on shares of Taiwan Semiconductor Manufacturing in a research report on Monday, July 6th. Finally, Susquehanna increased their price target on shares of Taiwan Semiconductor Manufacturing from $575.00 to $600.00 and gave the company a “positive” rating in a research report on Thursday. Three research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $490.00.

Get Our Latest Report on Taiwan Semiconductor Manufacturing

Taiwan Semiconductor Manufacturing Stock Up 1.0% NYSE:TSM opened at $402.49 on Tuesday. Taiwan Semiconductor Manufacturing Company Ltd. has a 1 year low of $223.70 and a 1 year high of $479.00. The stock has a 50-day moving average price of $426.76 and a two-hundred day moving average price of $379.20. The stock has a market cap of $2.09 trillion, a price-to-earnings ratio of 29.04, a PEG ratio of 0.95 and a beta of 1.36. The company has a current ratio of 2.49, a quick ratio of 2.31 and a debt-to-equity ratio of 0.16.

Taiwan Semiconductor Manufacturing (NYSE:TSM – Get Free Report) last released its quarterly earnings results on Tuesday, June 30th. The semiconductor company reported $4.28 EPS for the quarter. Taiwan Semiconductor Manufacturing had a return on equity of 40.88% and a net margin of 50.31%.The company had revenue of $39.89 billion for the quarter. As a group, equities analysts expect that Taiwan Semiconductor Manufacturing Company Ltd. will post 15.83 earnings per share for the current year.

Taiwan Semiconductor Manufacturing Increases Dividend The business also recently announced a quarterly dividend, which will be paid on Thursday, October 8th. Shareholders of record on Wednesday, September 16th will be issued a dividend of $1.1136 per share. This is an increase from Taiwan Semiconductor Manufacturing’s previous quarterly dividend of $0.95. The ex-dividend date is Wednesday, September 16th. This represents a $4.45 annualized dividend and a yield of 1.1%. Taiwan Semiconductor Manufacturing’s dividend payout ratio is 21.43%.

About Taiwan Semiconductor Manufacturing (Free Report)

Taiwan Semiconductor Manufacturing Company (TSMC) is a leading pure-play semiconductor foundry that provides wafer fabrication and related services to the global semiconductor industry. Founded in 1987 by Morris Chang and headquartered in Hsinchu, Taiwan, TSMC manufactures integrated circuits on behalf of fabless and integrated device manufacturers, offering contract chip production across a broad set of technologies and products.

TSMC’s service offering covers logic and mixed-signal process technologies, specialty processes for radio-frequency, power management and embedded memory, and advanced nodes used in mobile, high-performance computing and AI applications.

Recommended Stories Five stocks we like better than Taiwan Semiconductor Manufacturing The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding TSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM – Free Report).

Receive News & Ratings for Taiwan Semiconductor Manufacturing Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taiwan Semiconductor Manufacturing and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAmova Asset Management Americas Inc. Increases Stake in Toast, Inc. $TOST

NEXT HEADLINE »AlTi Global Inc. Acquires New Position in Golub Capital BDC, Inc. $GBDC

AlTi Global Inc. lowered its stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 54.7% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,563 shares of the healthcare product maker’s stock after selling 12,779 shares during the period. AlTi Global Inc.’s holdings in Abbott Laboratories were worth $1,085,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in shares of Abbott Laboratories by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock worth $21,995,501,000 after buying an additional 2,402,408 shares in the last quarter. State Street Corp lifted its stake in Abbott Laboratories by 2.1% in the 4th quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock worth $10,004,880,000 after purchasing an additional 1,627,791 shares in the last quarter. Capital International Investors boosted its holdings in shares of Abbott Laboratories by 2.6% during the 4th quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock worth $7,922,519,000 after purchasing an additional 1,614,706 shares during the last quarter. J. Stern & Co. LLP grew its position in shares of Abbott Laboratories by 12,439.6% in the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after purchasing an additional 39,005,451 shares in the last quarter. Finally, Capital Research Global Investors increased its holdings in shares of Abbott Laboratories by 1.0% in the fourth quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker’s stock valued at $4,907,523,000 after purchasing an additional 400,400 shares during the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes A number of equities analysts have weighed in on the company. Daiwa Securities Group lowered Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price objective on the stock. in a research note on Wednesday, April 22nd. Robert W. Baird started coverage on Abbott Laboratories in a report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price target on the stock. Weiss Ratings raised shares of Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, July 7th. Citigroup upped their price objective on shares of Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a report on Friday. Finally, Sanford C. Bernstein reduced their target price on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $118.61.

Read Our Latest Report on Abbott Laboratories

Insiders Place Their Bets In other news, Director Daniel J. Starks bought 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were purchased at an average price of $92.65 per share, with a total value of $926,500.00. Following the purchase, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Philip P. Boudreau bought 2,200 shares of the company’s stock in a transaction on Thursday, April 23rd. The stock was purchased at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the transaction, the chief financial officer owned 2,200 shares in the company, valued at $201,300. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Stock Up 1.0% Shares of ABT opened at $101.72 on Tuesday. The company’s 50-day moving average price is $90.28 and its 200 day moving average price is $101.84. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The firm has a market cap of $177.18 billion, a P/E ratio of 32.92, a price-to-earnings-growth ratio of 1.73 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. The company had revenue of $12.51 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. Abbott Laboratories’s revenue was up 13.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, sell-side analysts forecast that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Dividend Announcement The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. Abbott Laboratories’s payout ratio is presently 81.55%.

Abbott Laboratories Profile (Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Featured Articles Five stocks we like better than Abbott Laboratories The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

, /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced results for the second quarter 2026. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.

Key Second Quarter 2026 Results

Net earnings were $870 million, or $1.23 per diluted common share, up 60% year-over-year. Non-GAAP adjusted diluted net earnings per common share grew 8.0% to $1.94. Revenues increased 5.5% year-over-year to $6.3 billion. Non-GAAP core revenue increased 3.0% year-over-year and non-GAAP core revenue excluding respiratory testing revenue increased 4.5% year-over-year. Operating cash flow was $1.5 billion and non-GAAP free cash flow was $1.3 billion. Strong Q2 earnings performance and earlier-than-anticipated completion of Masimo acquisition enabling increased full year 2026 adjusted diluted net earnings per common share guidance. Rainer M. Blair, President and Chief Executive Officer, stated, "We delivered a better than expected second quarter, with core growth improving versus the first quarter and disciplined execution driving high-single-digits adjusted EPS growth. Our Life Sciences businesses delivered their strongest quarter in several years and while customer project timing impacted bioprocessing revenue, underlying order trends remained strong and bioprocessing orders grew mid-teens in the quarter."

Mr. Blair continued, "Looking ahead, continued end-market recovery and traction from our recent growth initiatives support our expectation to exit 2026 at a mid-single-digit core revenue growth rate. Longer term, Danaher's leading portfolio, capital deployment optionality and talented team — all powered by the Danaher Business System — position us to accelerate the impact of science and technology, help customers move from discovery to delivery faster, and create sustainable long-term shareholder value."

Third Quarter and Full Year 2026 Outlook

Danaher Corporation (the "Company") does not reconcile non-GAAP forecasted core sales growth, adjusted operating profit margin and adjusted diluted net earnings per common share to their respective, comparable measure prepared in accordance with U.S. generally accepted accounting principles (GAAP) because (except for estimated amortization of acquisition-related intangible assets of $0.5 billion for the third quarter and $1.9 billion for the year ending December 31, 2026 and the estimated impact of foreign currency on sales, which is estimated to decrease sales by 1.0% in the third quarter and increase sales by 0.5% in the full year, assuming the currency exchange rates in effect as of June 26, 2026) the additional elements that would be reflected in any such GAAP measures (such as the impact of currency exchange rates on profitability, future acquisitions, divested product lines, discrete tax adjustments, impairments, gains and losses on investments and the outcome of legal proceedings) are difficult to predict and estimate and are often dependent on future events that may be uncertain or outside of our control. The impact of these additional elements could be material to our results computed in accordance with GAAP.

For the third quarter 2026, the Company anticipates that non-GAAP core revenue will increase in the 2.0% to 3.0% range year-over-year.

For full year 2026, the Company expects non-GAAP core revenue will increase in the 3.0% to 4.0% range year-over-year. The Company is also increasing its full year adjusted diluted net earnings per common share guidance to a range of $8.45 to $8.60 versus previous guidance of $8.35 to $8.55.

Conference Call and Webcast Information

Danaher will discuss its second quarter results and financial guidance for the third quarter and full year 2026, including as applicable key assumptions with respect thereto, during its investor conference call today starting at 8:00 a.m. ET. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available in the same section of Danaher's website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.

The conference call can be accessed by dialing 833-419-0865, within the U.S. or +1 785-838-9333 outside the U.S. a few minutes before 8:00 a.m. ET and notifying the operator that you are dialing in for Danaher's earnings conference call (Conference ID: DHRQ226). A replay of the conference call will be available shortly after the conclusion of the call and until August 4, 2026. You can access the replay dial-in information on the "Investors" section of Danaher's website under the subheading "Events & Presentations."

ABOUT DANAHER

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them.

Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com.

NON-GAAP MEASURES AND SUPPLEMENTAL MATERIALS

In addition to the financial measures prepared in accordance with GAAP, this earnings release also contains non-GAAP financial measures. Calculations of these measures, explanations of what these measures represent and the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures, where applicable, and other information relating to these non-GAAP measures are included in the supplemental reconciliation schedule attached.

In addition, this earnings release, the slide presentation accompanying the related earnings call, non-GAAP reconciliations and a note containing details of historical and anticipated, future financial performance have been posted to the "Investors" section of Danaher's website (www.danaher.com).

FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION

Statements in this release that are not strictly historical, including the statements regarding the Company's anticipated financial results for the third quarter and full year 2026, the Company's expectations regarding growth and market recovery, the Company's positioning to create long-term shareholder value, and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things: the impact of the tariffs and related actions implemented by the U.S. and other countries, the impact of our debt obligations (including debt we incurred to finance the acquisition of Masimo Corporation) on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, the impact of global health crises, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (in each case, including with respect to our acquisition of Masimo Corporation), including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, security breaches or other disruptions of our information technology systems or violations of data privacy laws, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation, regulatory proceedings and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to our manufacturing operations, the impact of climate change, legal or regulatory measures to address climate change and other sustainability topics and our ability to address regulatory requirements or stakeholder expectations relating to climate change and other sustainability topics, risks relating to fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, labor matters and our ability to recruit, retain and motivate talented employees, U.S. and non-U.S. economic, political, geopolitical, legal, compliance, social and business factors (including the impact of elections, regulatory and policy changes or uncertainty, government shutdowns and military conflicts such as the conflict in the Middle East), disruptions and other impacts relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum provisions. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2025 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the second quarter of 2026. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

This press release may include descriptions of certain products and/or devices that have applications submitted and pending for certain regulatory approvals, or are available only in certain markets.

DANAHER CORPORATION AND SUBSIDIARIES

CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS

($ and shares in millions, except per share amounts)

(unaudited)

Three-Month Period Ended

Six-Month Period Ended

June 26, 2026

June 27, 2025

June 26, 2026

June 27, 2025

Sales

$           6,265

$           5,936

$          12,216

$          11,677

Cost of sales

(2,654)

(2,413)

(5,014)

(4,643)

Gross profit

3,611

3,523

7,202

7,034

Operating costs:

Selling, general and administrative expenses     

(2,072)

(2,360)

(3,932)

(4,218)

Research and development expenses

(412)

(403)

(799)

(782)

Operating profit

1,127

760

2,471

2,034

Nonoperating income (expense):

Other income (expense), net

(3)

(42)

(76)

(121)

Interest expense

(107)

(71)

(170)

(143)

Interest income

61

8

88

14

Earnings before income taxes

1,078

655

2,313

1,784

Income taxes

(208)

(100)

(414)

(275)

Net earnings

$              870

$              555

$           1,899

$           1,509

Net earnings per common share:

Basic

$             1.23

$             0.77

$             2.69

(a)

$             2.11

(a)

Diluted

$             1.23

$             0.77

$             2.68

$             2.10

(a)

Average common stock and common
equivalent shares outstanding:

Basic

705.3

716.5

706.6

716.4

Diluted

707.6

719.1

709.4

719.9

(a) Net earnings per common share amounts for the relevant three-month periods do not add to the six-month period amount due to rounding.

This information is presented for reference only. A complete copy of Danaher's Form 10-Q financial statements is available on the Company's website (www.danaher.com).

Diluted Net Earnings Per Common Share and Adjusted Diluted Net Earnings Per Common Share 

Three-Month Period Ended

Six-Month Period Ended

June 26, 2026

June 27, 2025

June 26, 2026

June 27, 2025

Diluted Net Earnings Per Common Share     
(GAAP)

$             1.23

$             0.77

$             2.68

$             2.10

Amortization of acquisition-related
intangible assets A

0.65

0.59

1.26

1.16

Fair value net (gains) losses on
investments B

0.01

0.06

0.12

0.19

Acquisition-related items C

0.15

—

0.18

—

Impairments D

—

0.60

—

0.62

Gain on a product line disposition E

—

—

—

(0.01)

Tax effect of the above adjustments F

(0.13)

(0.26)

(0.27)

(0.39)

Discrete tax adjustments G

0.03

0.03

0.03

0.02

Rounding

—

0.01

—

(0.01)

Adjusted Diluted Net Earnings Per
Common Share (Non-GAAP)

$             1.94

$             1.80

$             4.00

$             3.68

Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

A

Amortization of acquisition-related intangible assets in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in the amortization line item above):

Three-Month Period Ended

Six-Month Period Ended

June 26, 2026

June 27, 2025

June 26, 2026

June 27, 2025

Pretax

$              463

$              426

$              897

$              836

After-tax     

384

354

744

694

B 

Net (gains) losses on the Company's equity and limited partnership investments recorded in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in the fair value net (gains) losses on investments line above):

Three-Month Period Ended

Six-Month Period Ended

June 26, 2026

June 27, 2025

June 26, 2026

June 27, 2025

Pretax

$                 7

$               44

$               84

$              134

After-tax     

5

33

64

101

C 

Fair value adjustments to inventory, transaction costs deemed significant and pre-acquisition share-based and change-in-control payments, in each case related to the acquisition of Masimo Corporation ("Masimo") in the three and six-month periods ended June 26, 2026 ($108 million and $125 million pretax as reported in this line item, $95 million and $110 million after-tax). The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company's larger acquisitions) if it determines that such costs exceed the range of acquisition-related transaction costs typical for Danaher in a given period.

D 

Impairment charges related to a trade name in the Life Sciences segment recorded in the three and six-month periods ended June 27, 2025 ($432 million pretax as reported in this line item, $328 million after-tax) and a facility in the Biotechnology segment recorded in the six-month period ended June 27, 2025 ($15 million pretax as reported in this line item, $11 million after-tax).

E 

Gain on a product line disposition in the six-month period ended June 27, 2025 ($9 million pretax as reported in this line item, $7 million after-tax).

F 

This line item reflects the aggregate tax effect of all nontax adjustments reflected in the preceding line items of the table. In addition, the footnotes above indicate the after-tax amount of each individual adjustment item. Danaher estimates the tax effect of each adjustment item by applying Danaher's overall estimated effective tax rate to the pretax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires application of a specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment.

G 

Discrete tax adjustments and other tax-related adjustments for both the three and six-month periods ended June 26, 2026, include the impact of net discrete tax charges of $21 million related primarily to changes in estimates associated with prior period uncertain tax positions, partially offset by benefits from the release of reserves for uncertain tax positions resulting from audit settlements and the expiration of statutes of limitations during the six-month period. Discrete tax adjustments and other tax-related adjustments for the three-month period ended June 27, 2025, include the impact of net discrete tax charges of $22 million related primarily to changes in uncertain tax positions and other items. Discrete tax adjustments and other tax-related adjustments for the six-month period ended June 27, 2025, include the impact of net discrete tax charges of $12 million related primarily to the release of reserves for uncertain tax positions due to the expiration of statutes of limitations, partially offset by changes in uncertain tax positions and other items.

Sales Growth by Segment, Core Sales Growth (Decline) by Segment and Core Sales Growth Excluding Respiratory Testing

% Change Three-Month Period Ended June 26, 2026 vs. Comparable 2025 Period

Segments

Total Company

Biotechnology

Life Sciences

Diagnostics

Total sales growth (GAAP)

5.5 %

4.0 %

5.5 %

7.0 %

Impact of:

Acquisitions

(1.5) %

— %

— %

(4.0) %

Currency exchange rates

(1.0) %

(1.5) %

— %

(1.0) %

Core sales growth (non-GAAP)

3.0 %

2.5 %

5.5 %

2.0 %

Impact of respiratory testing

1.5 %

3.0 %

Core sales growth excluding respiratory
testing (non-GAAP)     

4.5 %

5.0 %

% Change Six-Month Period Ended June 26, 2026 vs. Comparable 2025 Period

Segments

Total Company

Biotechnology

Life Sciences

Diagnostics

Total sales growth (GAAP)

4.5 %

7.5 %

4.5 %

2.5 %

Impact of:

Acquisitions

(0.5) %

— %

— %

(2.0) %

Currency exchange rates

(2.0) %

(3.0) %

(1.5) %

(1.5) %

Core sales growth (decline) (non-GAAP)

2.0 %

4.5 %

3.0 %

(1.0) %

Impact of respiratory testing

2.0 %

5.0 %

Core sales growth excluding respiratory
testing (non-GAAP)

4.0 %

4.0 %

Note: Beginning with the Company's Quarterly Report on Form 10-Q for the second quarter of 2026, in addition to disclosing core sales growth, the Company is disclosing a new non-GAAP measure, titled "Core sales growth excluding respiratory testing." This new measure adjusts core sales to exclude revenues related to the sale of respiratory testing products in the Company's molecular diagnostics business in the Diagnostics segment. Demand for respiratory testing depends significantly on the severity levels of influenza and influenza-like illness in a given period, and these severity levels are not under management's control. As a result, presenting core sales on a basis that combines respiratory testing revenue with other Diagnostics business revenues can obscure underlying growth trends within the Diagnostics businesses.  The Company believes that presenting this additional measure will complement core sales, enhance investors' understanding of the historical and anticipated performance of the Diagnostics businesses and Danaher as a whole, including with respect to underlying growth trends, and facilitate comparisons of period-to-period performance. In addition, beginning with the Company's Quarterly Report on Form 10-Q for the third quarter of 2026, the Company intends to exclude from the core sales measures the impact, if any, of tariff refunds (related to tariff payments made in prior periods) that are returned, or expected to be returned, to customers. The Company believes this adjustment will help investors better understand underlying growth trends in the Company's business that otherwise may be obscured by the above-noted tariff-related impacts.

Non-GAAP Forward-Looking Information

% Change Three-
Month Period Ending
September 25, 2026
vs. Comparable 2025
Period

% Change Three-
Month Period Ending
December 31, 2026
vs. Comparable 2025
Period

% Change Year
Ending December 31,
2026 vs. Comparable
2025 Period

Core sales growth (non-GAAP)

Biotechnology

+Mid-single digit

+Mid-single digit

Life Sciences

+3.0% - +4.0%

+3.0% - +4.0%

Diagnostics

Flat

+Up slightly

Total Company

+2.0% - +3.0%

+Mid-single digit

+3.0% - +4.0%

Impact of respiratory testing

+2.5 %

Flat

+Low-single digit

Core sales growth excluding respiratory testing (non-GAAP)     

~+5.0%

+Mid-single digit

+Mid-single digit

Three-Month Period
Ending

September 25, 2026

Year Ending

December 31, 2026

Adjusted operating profit margin (non-GAAP)

 ~26.5  %

Adjusted diluted net earnings per common share (non-GAAP)

$8.45 - $8.60

Other Forward-Looking Information

Three-Month Period
Ending

September 25, 2026

Year Ending

December 31, 2026

Impact of currency exchange rates on sales H

~(1.0)%

~+0.5%

Amortization of acquisition-related intangible assets ($ in millions)     

~$(500)

~$(1,900)

Corporate expense I ($ in millions)

~$(90)

~$(360)

Interest expense, net J ($ in millions)

~$(115)

~$(310)

Effective tax rate

 ~17.0  %

 ~17.0  %

Average adjusted diluted shares (in millions)

~707

~709

H 

Impact of currency exchange rates on sales for the second quarter and full year 2026 assumes the currency exchange rates in effect as of June 26, 2026.

I 

Corporate expense represents the operating profit (GAAP) for the Other segment, which consists of unallocated corporate costs and other costs not considered part of management's evaluation of reportable segment operating performance.

J  

Interest expense, net is defined as interest expense net of interest income. This line item is an assumption rather than a forecast. The estimated interest expense, net is calculated assuming the currency exchange rates in effect as of June 26, 2026 are to prevail throughout the remainder of the period indicated and no change in the amount of commercial paper outstanding.

Pending SLMP LLC "StatLab" Acquisition

Earlier this month, Leica Biosystems, our anatomic pathology business, announced their intention to acquire StatLab, a leading manufacturer of products across the core histology workflow, from specimen collection through slide staining. The business has >85% recurring revenue and is complementary to Leica Biosystems' existing oncology instrument portfolio.

Below is some information on StatLab:

StatLab generated ~$250M in revenue for the full year 2025 The Company expects StatLab to have +high-single digit core sales growth over the long term The Company expects StatLab to be accretive to Adjusted diluted net earnings per common share (non-GAAP) in the 1st full year of ownership The Company expects to close this acquisition by the end of 2026, subject to customary closing conditions and regulatory approvals Historical Sales (Decline) Growth, Core Sales Growth and Core Sales Growth Excluding Respiratory Testing

% Change Three-Month Period Ended vs. Comparable 2024 Period

% Change Year
Ended
December 31,
2025 vs.
Comparable
2024 Period

% Change
Three-Month
Period Ended
March 27, 2026
vs. Comparable
2025 Period

March 28, 2025

June 27, 2025

September 26,
2025

December 31,
2025

Total sales (decline) growth
(GAAP)

(1.0) %

3.5 %

4.5 %

4.5 %

3.0 %

3.5 %

Impact of:

Acquisitions/divestitures

(0.5) %

— %

— %

0.5 %

— %

— %

Currency exchange rates

1.5 %

(2.0) %

(1.5) %

(2.5) %

(1.0) %

(3.0) %

Core sales growth (non-GAAP)

— %

1.5 %

3.0 %

2.5 %

2.0 %

0.5 %

Impact of respiratory testing

1.0 %

0.5 %

(0.5) %

1.5 %

0.5 %

2.5 %

Core sales growth excluding
respiratory testing (non-GAAP)     

1.0 %

2.0 %

2.5 %

4.0 %

2.5 %

3.0 %

Note: For the impact of respiratory testing, a positive amount represents a year-over-year headwind to core sales growth, and a negative amount represents a year-over-year tailwind to core sales growth.

Historical and Forward-Looking Respiratory Testing Sales

($ in millions)

 Three-Month Period Ended

Year
Ended
December
31, 2025 K

Three-Month Period
Ended

Three-Month Period
Ending

Year
Ending
December
31, 2026 K

March 28,
2025

June 27,
2025

September
26, 2025

December
31, 2025

March 27,
2026

June 26,
2026

September
25, 2026

December
31, 2026

Respiratory     
testing
sales L

~$650

~$300

~$500

~$500

~$1,900

~$500

~$250

~$325

~$500

~$1,600

K

Respiratory testing sales amounts for the relevant three-month periods may not add to the year-to-date period amount due to rounding.

L

Actual respiratory testing sales are rounded to the nearest $50 million.

Cash Flow and Free Cash Flow

($ in millions)

Three-Month Period Ended

Year-over-
Year Change

Six-Month Period Ended

Year-over-
Year Change

June 26, 2026

June 27, 2025

June 26, 2026

June 27, 2025

Total Cash Flow:

Net cash provided by
operating activities
(GAAP)

$            1,534

$           1,338

$           2,856

$           2,637

Total cash used in
investing activities
(GAAP)

$         (10,147)

$             (258)

$        (10,396)

$            (500)

Total cash provided by
(used in) financing
activities (GAAP)

$            7,273

$             (247)

$           7,319

$         (1,502)

Free Cash Flow:

Net cash provided by
operating activities
(GAAP)

$            1,534

$           1,338

 ~ 14.5 %

$           2,856

$           2,637

 ~ 8.5   %

Less: payments for
additions to property, plant     
& equipment (capital
expenditures) (GAAP)     

(269)

(248)

(506)

(493)

Plus: proceeds from sales
of property, plant &
equipment (capital
disposals) (GAAP)

—

4

—

10

Free cash flow (non-
GAAP)

$            1,265

$           1,094

 ~ 15.5 %

$           2,350

$           2,154

 ~ 9.0   %

Operating Cash Flow to
Net Earnings
Conversion Ratio:

Net cash provided by
operating activities
(GAAP)

$            1,534

$           1,338

$           2,856

$           2,637

Net earnings (GAAP)

870

555

1,899

1,509

Operating cash flow to net
earnings conversion ratio
(GAAP)

1.76

2.41

1.50

1.75

Free Cash Flow to Net
Earnings Conversion
Ratio:

Free cash flow from
above (non-GAAP)

$            1,265

$           1,094

$           2,350

$           2,154

Net earnings (GAAP)

870

555

1,899

1,509

Free cash flow to net
earnings conversion ratio
(non-GAAP)

1.45

1.97

1.24

1.43

We define free cash flow as operating cash flows, less payments for additions to property, plant and equipment ("capital expenditures") plus the proceeds from sales of plant, property and equipment ("capital disposals"). 

Statement Regarding Non-GAAP Measures

Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to investors by offering additional ways of viewing Danaher Corporation's ("Danaher" or the "Company") results that, when reconciled to the corresponding GAAP measure, help our investors:

with respect to the profitability-related non-GAAP measures, understand the long-term profitability trends of our business and compare our profitability to prior and future periods and to our peers; with respect to the non-GAAP measures related to core sales, identify underlying growth trends in our business and compare our sales performance with prior and future periods and to our peers; and with respect to free cash flow (the "FCF Measure"), understand Danaher's ability to generate cash without external financings, strengthen its balance sheet, invest in its business and grow its business through acquisitions and other strategic opportunities (although a limitation of free cash flow is that it does not take into account the Company's debt service requirements and other non-discretionary expenditures, and as a result the entire free cash flow amount is not necessarily available for discretionary expenditures). Management uses the non-GAAP measures referenced above to measure the Company's operating and financial performance, and uses core sales and non-GAAP measures similar to Adjusted Diluted Net Earnings Per Common Share, Adjusted Operating Profit and the FCF Measure in the Company's executive compensation program.

The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:

With respect to the profitability-related non-GAAP measures: Amortization of Intangible Assets: We exclude the amortization of acquisition-related intangible assets because the amount and timing of such charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate. While we have a history of significant acquisition activity we do not acquire businesses on a predictable cycle, and the amount of an acquisition's purchase price allocated to intangible assets and the related amortization term are unique to each acquisition and can vary significantly from acquisition to acquisition. Exclusion of this amortization expense facilitates more consistent comparisons of operating results over time between our newly acquired and long-held businesses, and with both acquisitive and non-acquisitive peer companies. We believe however that it is important for investors to understand that such intangible assets contribute to sales generation and that intangible asset amortization related to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Restructuring Charges: We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size, strategic nature and planning requirements, as well as the inconsistent frequency, of such plans) from the ongoing productivity improvements that result from application of the Danaher Business System. Because these restructuring plans are incremental to the core activities that arise in the ordinary course of our business and we believe are not indicative of Danaher's ongoing operating costs in a given period, we exclude these costs to facilitate a more consistent comparison of operating results over time. Other Adjustments: With respect to the other items excluded from the profitability-related non-GAAP measures, we exclude these items because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to Danaher's commercial performance during the period and/or we believe that such items may obscure underlying business trends and make comparisons of long-term performance difficult.  With respect to core sales, (1) we exclude the impact of currency translation because it is not under management's control, is subject to volatility and can obscure underlying business trends, and (2) we exclude the effect of acquisitions and divested product lines because the timing, size, number and nature of such transactions can vary significantly from period-to-period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult. Please see "Sales Growth by Segment, Core Sales Growth (Decline) by Segment and Core Sales Growth Excluding Respiratory Testing" above for an explanation on why we exclude respiratory testing revenues from the non-GAAP measure "Core sales excluding respiratory testing". In addition, beginning with the Company's Quarterly Report on Form 10-Q in the third quarter of 2026, the Company intends to exclude from core sales the impact of tariff refunds related to prior period tariffs that are returned, or expected to be returned, if any, to customers as the Company believes these amounts may obscure underlying business trends.  With respect to the FCF Measure, we deduct payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to demonstrate the amount of operating cash flow for the period that remains after accounting for the Company's capital expenditure requirements. SOURCE Danaher Corporation

Advanced compute power, built on NVIDIA infrastructure, enables real-time decision support during the procedure

FDA-cleared Instrument Exit Point (IEP), the first real-time AI application for robotic procedures from Medtronic, advances a precise, predictable, and personalized future for surgery

, /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, is presenting an early look at its next-generation compute platform for the operating room. Touch Surgery™ Aide — an AI-native surgical computing platform that powers the Touch Surgery™ ecosystem — enables real-time artificial intelligence during procedures. Touch Surgery™ Aide will be shared at the Society of Robotic Surgery (SRS) 2026 Annual Meeting in Florida, July 23-26.

Touch Surgery(TM) Aide and the Touch Surgery(TM) ecosystem

Hugo(TM) Robotic Assisted Surgery system console and Touch Surgery(TM) ecosystem with the next-generation compute platform Touch Surgery(TM) Aide Built on years of experience, the Touch Surgery™ ecosystem brings insight to surgery, in more than 1,500 operating rooms worldwide. It connects the entire surgical journey: bridging pre-operative planning and training, intra-operative tele-mentoring and tele-proctoring, and AI-powered post-operative insight, simplifying workflows and extending access beyond individual ORs.

Touch Surgery™ Aide expands the Touch Surgery™ ecosystem with next-generation computing capabilities, enabling multimodal AI-driven support during surgery. This provides surgeons with access to actionable insights during procedures, supports case review, and helps inform continuous improvement in clinical decision-making.

"Real-time AI marks a new frontier for healthcare — it is a fundamental evolution in how surgery is supported, moving from technology that assists the surgeon's hand to technology that helps teams work smarter, move faster, and deliver greater impact in the moment," said Jim Peichel, Chief Technology Officer at Medtronic.

Touch Surgery™ Aide incorporates NVIDIA's accelerated computing infrastructure, leveraging the company's Holoscan, CUDA, and TensorRT to deliver AI-powered insights in the moment, supporting surgical decision-making when it matters most. Touch Surgery™ Aide combines computer vision, multimodal AI, and accelerated inference to process surgical video and procedural context in real time. This enables multiple AI applications to run simultaneously during a live procedure, processing and acting on surgical data in the moment. It brings intelligent, increasingly automated support in the OR, and is designed to continuously learn and evolve. 

Medtronic's first real-time AI application for robotic surgery
Instrument Exit Point (IEP) is an AI application that runs on Touch Surgery™ Aide, for use with the Hugo™ robotic-assisted surgery (RAS) system. It received U.S. Food and Drug Administration (FDA) clearance.

Using computer vision, IEP provides a visual notification when select instruments move beyond the visible field of view during a robotic procedure. As the first real-time AI application to run on Touch Surgery™ Aide, IEP represents an early step in bringing AI-enabled support into robotic surgery, with the platform designed to support expansion into laparoscopic surgery over time.

Medtronic continues to progress the capabilities of the Hugo™ robotic-assisted surgery (RAS) system. In December 2025, the Hugo™ RAS system received FDA clearance for use in urologic surgical procedures, bringing a versatile robotic-assisted platform to U.S. surgeons and health systems. In June 2026, Medtronic announced 510(k) submissions to expand the use of the Hugo™ RAS system into general and gynecologic specialties in the U.S. The Hugo™ RAS system continues to have a growing global impact and has been used in tens of thousands of procedures across more than 35 countries in six continents. 

Transforming the future of surgery
This is an early step in a broader effort to bring AI into more of what happens in the operating room. Over time, Medtronic expects the platform to support a growing range of real-time AI applications, connect with other Medtronic technologies in the OR, and turn the data from every case into insight for surgical teams and the hospitals they work in.

"Surgery is on the cusp of a generational shift, powered by AI and advanced compute," said George Murgatroyd, General Manager & Vice President, Digital Technologies within the Surgical business at Medtronic. "The Touch Surgery™ ecosystem, powered by Touch Surgery™ Aide, establishes a platform for a new generation of embedded connectivity, seamlessly integrating advanced capabilities into surgical workflows and reinforcing Medtronic's commitment to delivering the best possible care, for every patient, anywhere."

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:

Gary Jeanfaivre      

Ingrid Goldberg

Public Relations

Investor Relations

+1-203-556-0777

+1-763-505-2696

SOURCE Medtronic plc

Sintana Energy Inc (TSX-V:SEI, OTCQB:SEUSF, FRA:3ZX1, AIM:SEI) said the exploration timetable for its offshore Uruguay interests has been extended by a year, while an Argentine offshore licensing opportunity moved towards a formal international tender.

Uruguay’s state-owned energy company and regulator ANCAP agreed to suspend the initial exploration period for the AREA OFF-1 block, pushing its expiry date to 23 August 2027. Operator Chevron requested the extension after delays in obtaining environmental approval for a planned 3D seismic programme.

The first seismic acquisition season was completed before the end of April, with a second scheduled to begin in the fourth quarter of 2026. Sintana said the full dataset must be acquired, processed and interpreted before an optimal exploration drilling decision can be made.

Separately, Argentina has instructed its National Secretariat of Energy to call an international public tender for the CAN-200 area in the North Argentine Basin. The process follows a February 2025 expression of interest from Sintana group company Challenger Energy and is a necessary step before a potential exploration permit can be awarded.